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This Thesis consists of two parts: in the first part, I studied the efficacy of fluoxetine on the 
recovery from spinal cord injury in rats; in the second part, I evaluated the effects of envi-
ronmental enrichment on visual cortex plasticity in the aging rat. Both of the studies resulted 
in peer-reviewed publication (Scali et al., 2012; 2013). 
!
When I started my PhD program, spinal cord injury was a completely new field in my lab. 
Under my Supervisor, Prof. Lamberto Maffei's, suggestion I moved to Cambridge (UK) to 
learn the necessary skills to bring the technique of the lesion model in Pisa laboratory, and 
after a necessary training I was able to start the experiments. 
I chose to focus the main part of my dissertation on spinal cord injury because I devoted to 
this project most of my time. The study related to visual cortex plasticity in the aging rat is 












“When you examine a man with a dislocation of a vertebra of his neck, and you find him un-
able to move his arms, and his legs. His penis is erect; urine drips from his penis unknowing-
ly. Then you have to say: A disease one cannot treat.” 
Edwin Smith Surgical Papyrus, Seventeenth Century B.C 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Introduction 
Chapter 1: The spinal cord 
Spinal cord anatomy 
The spinal cord is the part of the central nervous system that controls limb and trunk move-
ments and which receives sensory information from these areas; moreover, the spinal cord has 
an important role in viscera and blood vessel function of thorax, abdomen and pelvis. It looks 
like a dorsoventrally flattened cylinder coated by the meninges (dura mater, arachnoid and pia 
mater) and it lies inside the vertebral canal, where it extends from the base of the skull to the 
first lumbar vertebra. When observed in a transverse section, the cord appears in the shape of 
a butterfly constituted by central grey matter (which contains nerve cell bodies) surrounded 
by external white matter (formed by the axons of ascending and descending pathways and 
glial cells). The central grey locally organizes motor behavior and regulates sensory signals: 
the dorsal horns of the butterfly contain the cell bodies of ascending sensory fibers, while the 
ventral horns contain the motoneurons (Barson and Sands, 1977). The central region, which 
connects the dorsal and ventral horns, is called intermediate grey matter and surrounds the 
central canal (which is remnant of the embryological ventricular system and is continuous 
with the fourth brain ventricle; Figure 1). 
 The human spinal cord can be divided in 31 segments along its rostral-caudal axis, 
grouped by anatomists in five sections: cervical (C1-C8), thoracic (T1-T12), sacral (S1-S5), 
lumbar (L1-L5) and coccygeal (Co1). In other species the number of segments is different, as 
in the rat, which has 34 segments (C1-C8; T1-T13; S1-S6; L1-L4; Co1-Co3). Each segment is 
associated with a pair of sensory (arising from the dorsal horns) and motor (arising from the 
ventral horns) nerves that relay signals between periphery and the central nervous system; the 
nerve rootlets arising from the cord are bundled together so that one pair of spinal nerves 
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emerges from each segment. Because of the higher necessity for neural computation in limb 
regions, the grey matter is larger in cervical and lumbar areas, where the brachial and lum-
bosacral plexuses arise. 
 The central grey of was divided by Bror Rexed in ten layers, based on their cytoar-
chitercture (Rexed, 1952; 1954). The layers, called laminae, are organized in a dorsal-ventral 
fashion, except for lamina X, which is the neuroglial tissue that surrounds the central canal 
(Figure 1). 
Figure 1. Transverse section of human spinal cord. Grey matter is indicated in grey color. Numbers indicate lam-
inae. Adapted from Watson et al., 2009. 
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 The dorsal horn is formed by laminae I to VI: laminae I-IV are the recipient of sensory 
input associated with cutaneous stimuli; lamina V is the thickest layer of the dorsal horn and 
receives afferents from viscera, skin and muscles, while lamina VI is primarily concerned 
with proprioceptive sensations that signal limb position and movement and is found only in 
the segments corresponding to cervical and lumbar enlargements. Lamina VII occupies the 
intermediate grey matter and the dorsal part of the ventral horn; it is constituted by interneu-
rons that connect to motoneuronal pools and is involved in the control of posture and move-
ment. In lamina VIII, propriospinal interneurons modulate motor activity, connecting mo-
toneurons on the same and opposite side of the spinal cord. Lamina IX lies within the ventral 
horn and represents the main motor area. Axons from this region exit from the ventral root 
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and innervate muscle fibers. Lastly, lamina X, which surrounds the central canal, receives no-
ciceptive information form skin and viscera (Grau et al., 2006; Watson et al., 2009). 
 The white matter is formed by longitudinally running fibers and glia. Groups of fibers 
can be classified based on the anatomical position and function: small bundles of axons locat-
ed in a given area are defined fasciculi, while a group of fasciculi sharing common features is 
called funiculus; when a group of nerve fibers have the same origin, course, termination and 
function, the group is named tract. A group of tracts with a related function constitutes a 
pathway. 
 Grey matter horns divide the white matter in three distinct regions: dorsal, lateral and 
ventral columns (Figure 1). Dorsal columns are located between dorsal horns and are separat-
ed by the dorsal median sulcus; they are principally constituted by the central processes of 
dorsal root ganglion cells, which form the direct pathway conveying skin sensation and pro-
prioception from the limbs and trunk to the brain. The direct pathway is constituted by the 
cuneate and gracile fasciculi, that ascend ipsilaterally and synapse respectively in the cuneate 
and gracile nuclei in the medulla oblongata; here, the fibers originating from these nuclei 
cross the midline and constitute the medial lemniscus pathway, which terminates in the ven-
troposterolateral nucleus of the thalamus. The gracile fasciculus contains the afferent fibers 
arising from lower trunk and extremities below the T6 spinal cord segment. In C1-T6 spinal 
cord segments, the gracile fasciculus is located medially with respect to the cuneate fascicu-
lus, which constitutes the afferent pathway ascending from the upper trunk and extremities. 
These pathways are involved in transmitting sensations of discriminatory touch, deep pres-
sure, proprioception, sense of position of joints, stereognosis and vibration. In rodents and 
many non-primate mammals, the ventral-most part of the dorsal column contains the dorsal 
corticospinal tract (CST), a bundle of fibers that originates primarily from the layer V of pri-
mary motor, premotor and somatosensory cortical areas; the axons of pyramidal neurons then 
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pass through the internal capsule, cerebral peduncle, longitudinal fibers of the pons, and 
medullary pyramid, to reach the caudal end of the brain stem, where most of them cross to the 
opposite side in the pyramidal decussation and then lie in the ventral part of the dorsal column 
of the spinal cord. In most mammals, the majority of CST fibers terminate on the neurons of 
the medial parts of the base of the dorsal horn and the intermediate grey matter (Rexed’s lam-
inae III-VI), which then send connections to lamina IX motoneurons. Differently from ro-
dents, in primates and carnivores the major CST bundle is found in the dorsal part of the lat-
eral column (see Figure 2); moreover, some of its fibers make direct synaptic connections 
with motoneurons in lamina IX (up to 20% in humans): this is correlated with the develop-
ment of ‘skilled’ motor capacities, such as an increased dexterity of distal musculature 
(Heffner and Masterton, 1983; Watson et al., 2009); it is important to underline that in ro-
dents, CST axons mediate fine movements of the limbs, whereas in humans the corticospinal 
tract is much more involved in almost all aspects of voluntary motor control (Blesch and 
Tuszynski, 2009). 
 The lateral and ventral columns are formed by a variety of ascending and descending 
fiber groups. The principal ascending tract is the spinothalamic tract, which transmits noci-
ceptive, thermal, non-discriminative touch and pressure sensations to the somatosensory areas 
of the thalamus; another important ascending tract is the spinocerebellar one, which conveys 
informations from Golgi tendons and muscle spindles to the cerebellum, for the control of 
movement coordination. The descending tracts, besides CST tract (in primates), include: the 
rubrospinal tract, that arises form the red nucleus and is involved in the control of skilled 
movements (Whishaw et al., 1998); the reticulospinal tract, which originates in the reticular 
formation of the romboencephalon and is involved in postural control and modulation of 
some sensory and autonomic functions (Tracey, 2004); the vestibulospinal tract, that repre-
sents the main initiator of coordinated postural extensor activity in the limbs and trunk (Pom-
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peiano, 1972); the raphespinal tract, that descends from raphe in medulla oblongata and has 
neuromodulatory influences on motor, autonomic, reproductive and excretory function and is 
also involved in modulating perception to pain (Tracey, 2004).  
 As well as these long ascending and descending projections, in the white columns 
there are many fibers, called propriospinal, that connect one spinal cord segment with another. 
These fibers lie very close to the grey matter and participate in a variety of physiological and 
behavioral processes, such as modulation of afferent and descending inputs to the central pat-
tern generators (CPG) for locomotion and respiration, as well as autonomic functions like vis-
ceroreception and pain perception. The largest propriospinal pathways connect the brachial 
and lumbosacral enlargements to coordinate limb movements (Watson et al., 2009). 
Figure 2. Approximate location of some ascending and descending tracts in rat and human spinal cord. (a) rat; 
(b) human. The diagrams are not drawn to scale. Dotted lines indicate areas where tracts appear to overlap. 
Left side: sensory; right side: motor. Adapted from Watson et al., 2009. 
!
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Spinal cord injury 
General pathophysiology 
Spinal cord injury (SCI) is the most common cause of invalidity in young adults. This condi-
tion affects 2.5 million people in the world, with an incidence of 130000 new cases every year 
(Thuret et al., 2006). The high majority of injuries have a traumatic origin (motor vehicle 
crashes, falls, violence and sport accidents) and affect principally young adults in the 15-29 
years old age group. Non-traumatic injuries, as those caused by cancer, ischemia and multiple 
sclerosis, seem to be more related with old age. Moreover, the prevalence is 3.8 folds higher 
in males than females (Wyndaele and Wyndaele, 2006; van den Berg et al., 2010). Since quite 
half of injured patients is represented by young men that become unable to continue their job 
career and start to need assistance and special medical cares, social and economic costs of SCI 
are enormous. 
 Spinal cord injuries can be classified depending on the severity of the lesion (complete 
or incomplete), the segmental level (cervical, thoracic, lumbar or sacral) and the kind of insult 
that mechanically induced the injury (flexion, extension, rotation, compression or a combina-
tion of these forces; Schwab and Bartholdi, 1996). From the anatomical point of view, com-
plete lesions are quite rare; anyway, when the damage to neural tissue is huge, a complete loss 
of function related to the interested area can be observed. The severity of the injury can be 
addressed analyzing the neurological outcome, and various scales can be adopted; for in-
stance, the ASIA (American Spinal Injury Association) Impairment Scale, which is graded 
from A (complete sensorimotor injury) to E (normal), is widely accepted (Fawcett et al., 
2006). Concerning the segmental level, cervical injuries are generally the most common. In 
very severe cases, cervical SCI causes tetraplegia, a condition that involves loss of function of 
upper and lower extremities, trunk and pelvis; however, only one third of patients experience 
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this state, while paraplegia, that afflicts principally the lower part of the body, is more fre-
quent (Wyndaele and Wyndaele, 2006). 
 In spite of such a variety of causes and typologies, SCI pathophysiology seems to fol-
low the same paradigm after the first insult (primary damage). In general, this process can be 
divided in an acute phase characterized by intertwined cellular death, hemorrhage and begin-
ning of inflammatory response, and a chronic phase, in which the consequences of secondary 
damage started during the acute phase finally establish the formation of a glial scar at the in-
jury site and, sometimes, of a cystic cavity full of liquid (Figure 3).  
Figure 3. Diagram representing the spinal cord at the chronic stage of injury (adapted from Thuret et al., 2006). 
!
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The time at which a lesion reaches the “chronic stage” varies between species. Clinical data 
suggest that, for humans, an injury can be considered chronic 12 months after the first insult 
(Fawcett et al., 2006). The mechanisms of secondary injury have been deeply dissected in an-
imal models of SCI (see below); nevertheless, recent studies indicate that similar mechanisms 
occur in humans as well (see Hagg and Oudega, 2006 for a review; Table 1). 
!
Table 1. Similarities and differences between rodent and human response after SCI (adapted from Hagg and 
Oudega, 2006). 
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After initial trauma, cells near the site of injury immediately die. Disruption of blood flow due 
to death of endothelial cells brings to hemorrhage and intravascular thrombosis, which in 
combination with loss of autoregulation (Senter and Venes, 1979) and vasospasm of intact 
vessels (Attar et al., 2001), causes the anoxia and hypoperfusion of spinal tissue surrounding 
lesion and the appearance of edema (Tator and Fehlings, 1991). Vascular damage is one of the 
principal causes of secondary injury (Mautes et al., 2000): the high metabolic demand of grey 
matter cannot be satisfied because of incipient ischemia, moreover loss of autoregulation of 
microvascular tone leads to higher susceptibility of neurons to changes in systemic arterial 
pressure, a pretty frequent phenomenon in SCI patients (Levi et al., 1993). This process is 
Secondary response Rodent Human
Vascular response Hemorrage, angiogenesis Hemorrage, angiogenesis
Inflammation Extensive Much less pronounced, despite similar 
cytokine expression
Demyelination Yes Yes, but perhaps less pronounced
Axonal degeneration Some die-back and Wallerian degeneration Wallerian degeneration much more protrac-
ted
Glial scar Extensive, with astroglial CSPG Not extensive, CSPFs mostly in blood ves-
sels
Cyst formation Rat yes; mouse no Yes
Schwann cell response Some invasion Extensive Schwannosis
CSPG: chondroitin sulphate proteoglycans
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worsen by formation of free radicals (such as reactive oxygen species and peroxynitrite), 
compounds that induce peroxidation of lipid components of cellular membrane producing the 
disaggregation of membrane itself and the formation of new reactive species that continue the 
cascade (Cayli et al., 2004); besides, free radicals can damage mitochondrial respiratory chain 
enzymes, inducing the apoptotic death of the cell (Cuzzocrea et al., 2001; Tanaka et al., 2005). 
 The breakdown of blood-spinal cord barrier allows the entrance of inflammatory cells 
in the site of injury (Mautes et al., 2000; Whetstone et al., 2003; Habgood et al., 2007). The 
inflammatory response is a complex mechanism: it is initiated by the recruitment of neu-
trophils starting few hours after the SCI by chemoattractant molecules (chemokines, cy-
tokines, adhesion molecules) that are increased by lysis of necrotic cells (Campbell et al., 
2002; Kwon et al., 2004; Fleming et al., 2006; Donnelly and Popovich, 2008); neutrophils are 
then followed by macrophages derived from resident microglia (Popovich et al., 2002) and 
blood-born macrophages (Carlson et al., 1998). Infiltration of inflammatory cells allows the 
phagocytosis of tissue debris; moreover, these cells start to release pro-inflammatory cy-
tokines (such as tumor necrosis factor alpha (TNFα) and interleukins 1 and 6), cytotoxic mol-
ecules (such as reactive oxygen species, nitric oxide) and proteolytic enzymes (such as metal-
loproteinases) that supply inflammatory responses and induce secondary damage (Schnell et 
al., 1999; Xu et al., 2001; Noble et al., 2002; Donnelly and Popovich, 2008). 
 An other important process related with the secondary damage of spinal cord is excito-
toxicity due to change in ionic conductance and release of neurotransmitters. Cell lysis, de-
myelination due to apoptosis of oligodendrocytes and depolarization of neuronal membrane 
leads to increased intracellular concentration of sodium and calcium and extracellular concen-
tration of potassium (Liu et al., 2011). This creates a loop in which increased intracellular cal-
cium concentration allows the exocytosis of glutamate from synaptic vesicles, that in turn ac-
tivates NMDA (N-methyl-D-aspartate) or AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxa-
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zole- propionic acid)/kainate receptors. The hyperactivation of these ionotropic receptors re-
sults in increased intracellular sodium levels in neurons and astrocytes, that can cause the 
death of the cell due to water influx and lysis through depolarization (Matyja et al., 2005). 
Moreover, calcium influx trough NMDA and AMPA receptors provokes axonal injury and 
eventual apoptosis or necrosis via an increase in the activation of cellular enzymes, mitochon-
drial damage, acidosis, and production of free radicals (Schanne et al., 1979; Mody and Mac-
Donald, 1995; Das et al., 2005). 
 As mentioned above, oligodendrocytes principally die by apoptosis after injury 
(Emery et al., 1998); oligodendrocyte death can be caused by microglial activation (Li et al., 
2005), axonal degeneration (that causes the loss of trophic support to the oligodendrocytes; 
Barres et al., 1993) or interaction between NGF, which is increased by lesion, and pro-apop-
totic receptor p75, which is expressed by oligodendrocytes (Casha et al., 2001). This process 
provokes demyelination of spared axons, with a consequent impairment of signal conductance 
and general physiology of the neuron, that eventually loses its function and degenerates 
(Waxman, 1989). Besides, a great loss of ascending and descending fibers is observed in the 
white matter one month after SCI (Bao and Liu, 2003; Wingrave et al., 2003; Araki et al., 
2004; Iwata et al., 2004), with denervation and retraction of proximal axons.  
 The pathophysiology of the acute phase is completed by reactive gliosis. In response 
to cytokines and other molecules produced by inflammatory cells and degenerating axons, 
astrocytes start to overexpress the glial fibrillary acidic protein (GFAP) and to proliferate 
(Giulian and Lachman, 1985; Nishino et al., 1993; Chiang et al., 1994; Kahn et al., 1995; 
Hama et al., 1997; Rostworowski et al., 1997). These cells become hypertrophic and their 
processes start to overlap together with infiltrating fibroblasts, Schwann cells, macrophages 
and glial progenitors such as NG2 positive cells (Jones et al., 2002; Guest et al., 2005; Goritz 
et al., 2011), creating a glial scar between the spinal cord and the rest of the body in the at-
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tempt to preserve the fragile neural tissue from further damage (Fitch et al., 1999; Myer et al., 
2006). Unfortunately, the glial scar represents also a barrier for axonal regeneration, a condi-
tion that is reinforced by the production of transmembrane and secreted inhibitory molecules 
such as proteoglycans that form the extracellular matrix (ECM) (Jones et al., 2003), ephrin-B2 
(Bundesen et al., 2003), semaphorin 3A (Pasterkamp et al., 2001), and tenascin (Apostolova 
et al., 2006) by the same astrocytes. 
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Experimental models of SCI 
In order to study the mechanisms leading to secondary damage and to create tools to investi-
gate the efficacy of possible therapies, researchers have developed several animal models 
mimicking different aspects of human SCI since Galen (2nd century A.D., Siegel, 1973). In-
jury models can be distinguished on the basis of the specimen, the level of injury and the kind 
of injury itself. Rodents and feline are the most used because of economic and practical ad-
vantages, although non-human primate models are emerging as the best choice for their simi-
larities with humans (see Courtine et al., 2007 for a review). 
!
Contusion and compression models 
The models that best resemble the characteristics of human disease are those based on contu-
sion or compression of spinal cord tissue, as the majority of patient lesions derive from blunt 
trauma and displacements of vertebral bone. These methods induce a mild to complete neuro-
logical lesion with the appearance of scar surrounding a fluid-filled cyst, then they are partic-
ularly suitable to study neuroprotective agents, tissue replacement and injury pathophysiology 
in general. 
 The first experimental contusion injury model was proposed by Allen in 1911: a 
weight-drop insult was applied on the exposed dorsal spinal cord of a dog, causing the contu-
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sion and the displacement of neural tissue in the vertebral canal (Allen, 1911). This approach 
was then adapted to the rat (Gruner, 1992) and led to the development of the NYU/MASCIS 
(New York University Multicenter Animal Spinal Cord Injury Study) Impactor, a device that 
allows to induce a reproducible contusive damage to the rat spinal cord in controlled condi-
tions (spinal level, drop weight, impact strength; Basso et al., 1996). Other tools created to 
induce contusion injuries in rodents are the OSU (Ohio State University) Impactor (Bresnahan 
et al., 1987; Stokes, 1992), which employs an electromechanical impact probe controlled by 
computer feedback, and the IH (Infinite Horizon) Impactor (Scheff et al., 2003), a device that 
applies a force-defined impact to the cord with a stainless steel-tipped impounder. All these 
instruments share similar advantages (reliability of performance and results, possibility to set 
and check all the parameters during and after the experiment, low maintenance costs), as well 
as similar limitations: while the force that induces lesion in humans is usually applied on the 
ventral surface of the cord or in a centripetal way (e.g. by torsion of the cord), the impactors 
described above act on the dorsal, surgically exposed surface of the neural tissue. 
 An alternative strategy to induce a lesion that might be more similar to human blunt 
SCI is represented by the clip compression model: after exposure by dorsal laminectomy, the 
spinal cord is compressed along the dorso-ventral axis between the arms of a modified an-
eurysmal clip (Rivlin and Tator, 1978; Joshi and Fehlings, 2002a; 2002b). The force and dura-
tion of compression are directly related with the functional outcome, so the severity of the le-
sion can be easily modulated; on the other hand, the principal disadvantage of this technique 
is represented by the difficulty of surgical manipulation of the cord. Compression injury can 
also be elicited by means of an inflated microscopic balloon inserted in the epidural space for 
a period that can vary from minutes (leading to a reversible functional lesion, Nesathurai et 
al., 2006) to hours (leading to irreversible damage because of secondary consequences de-
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rived form initial compression, Lim et al., 2007). This method allows to operate on different 
species, from rodents to primate, and kindly resembles human injury. 
!
Transection models 
Transection models are based on the surgical cut of the spinal cord and can be divided in 
complete and partial transection models. 
 In complete transections, rostral and caudal segments of the spinal cord are fully dis-
sociated; these models are used to mimic human complete injury, though in patients a com-
plete anatomical lesion is very rare also in case of total functional loss. Nevertheless, a com-
plete transection allows to evaluate the efficiency of treatments aimed at inducing axonal re-
generation without the risk of misleading results due to the contribution of spared connections 
(Alilain et al., 2012; Lu et al., 2012). A complication related to complete transection models is 
the high post-operative care request to maintain critical physiological functions (as feeding 
and bowel/bladder function) and to control complications as infections, pain and dehydration 
of the animal. 
 Partial transections models are often criticized as they are less likely to represent hu-
man lesions than contusion models. On the other hand, incomplete transection is still a widely 
used model because it represent a valuable tool to study the contribution of particular tracts to 
motor and sensory function (e.g. CSTs, Bradbury et al., 2002; García-Alías et al., 2009) and to 
assess the effectiveness of pro-regenerative treatments; moreover, in case of dorsal or lateral 
hemisection, it allows to compare the injured circuit response with that of the healthy, unin-
jured counterpart (Muir and Whishaw, 2000; Anderson et al., 2007). 
!
Ischemia models 
Ischemic insults can be recapitulated by in vitro and in vivo models.  
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 Organotypic spinal cord slices and specific cellular line cultures can be maintained 
under hypoxic conditions, enabling researchers to analyze the molecular cascades that lead to 
neuronal cell death (An et al., 2011; Lian Jin et al., 2011). Compared to in vivo models, the 
advantage in the use of slice and cell cultures is that they are far less expensive and do not 
require postoperative cares, while a limit is represented by the possibility to dissect just an 
aspect a time of a complex pathology as spinal cord injury. 
 Hypoxia and ischemic damage can be induced also in vivo by means of vascular com-
pression; the most characterized model is based on the insertion of a Fogarty balloon in the rat 
thoracic descending aorta; blood flow is blocked at the level of the subclavian artery by bal-
loon inflation, then the spinal cord is reperfused. In rats, this kind of insult induces paraplegia 




Chapter 2: Plasticity 
Neural plasticity can be defined as the ability of the nervous system to functionally and struc-
turally reorganize itself in response to experience: “The whole plasticity of the brain sums it-
self up in two words when we call it an organ in which currents pouring in from the sense-or-
gans make with extreme facility paths which do not easily disappear” (James, 1890). 
 In 1960s and 1970s, Hubel and Wiesel examined the plasticity of cat and monkey vis-
ual systems and identified a ‘critical period’ during which deprivation of normal visual expe-
rience through the closure of an eyelid by surgical suture (monocular deprivation, MD) irre-
versibly altered neuronal connections and functions in the visual cortex (Wiesel and Hubel, 
1963; Hubel and Wiesel, 1970; Hubel et al., 1977). Since then, the existence of critical peri-
ods in early postnatal life during which neural circuits display a heightened plasticity in re-
sponse to external stimuli has been established for various brain regions subserving major be-
havioral functions, as for instance the organization of auditory maps for sound localization in 
barn owls (Knudsen and Knudsen, 1990), birdsong in zebrafinches (Brainard and Doupe, 
2002) and language learning in humans (Newport et al., 2001. See Berardi et al., 2000 and 
Hensch, 2004 for a comprehensive review). Concerning the motor system, an example of crit-
ical period is represented by the sensitivity to tail suspension, a manipulation that allows 
hindlimb unloading: in young rats (postnatal day 8-13), tail suspension leads to permanent 
motor impairment in the spinal cord, while it is innocuous in older animals (Walton et al., 
1992). 
 During critical periods, neural circuits reach maturity: starting from an initial pool of 
less precise connections, experience models neural circuits stabilizing some connections and 
removing others (Holtmaat and Svoboda, 2009; Fu and Zuo, 2011). Because of this “en-
hanced-plasticity status”, the recovery from injury is much more pronounced in the early 
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postnatal phase (Nicholls and Saunders, 1996; Payne and Lomber, 2001; Chen et al., 2002; 
Dumas et al., 2002; Mladinic et al., 2009; Choksi et al., 2010). When the development is 
completed, plasticity wanes in favor of the formation of stable, reliable networks with precise 
circuitries and connections. In the adult brain, even if decreased, synaptic plasticity continues 
through modifications of synaptic strength, as well as through formation and elimination of 
synapses (Holtmaat and Svoboda, 2009; Chen and Nedivi, 2010). 
 In the past years, a big effort was made to investigate the mechanism underlying the 
enhanced plasticity of immature circuits and the possibility to manipulate the capability of 
neural networks to respond to experience and insults after the closure of critical periods. Sev-
eral factors have been identified using the visual system as a paradigmatic model (see Berardi 
et al. 2003; Tropea et al., 2009; Levelt and Hubener, 2012). Among them, the excitatory/in-
hibitory balance emerges as a critical regulator for neural plasticity. Inhibitory circuits sculpt 
the pattern and timing of neuronal electrical activity; for instance, the increase of GABAergic 
transmission in the visual cortex defines the opening and the closure of the critical period for 
ocular dominance plasticity (Hensch, 2005): when GABAergic input is reduced during devel-
opment, as in mice knockout for GAD65 (the synaptic biosynthetic enzyme of GABA), the 
visual cortex does not respond to experience modification such as MD (Hensch et al., 1998). 
A similar reduction of MD sensitivity can be achieved increasing the efficacy of glutamatergic 
transmission during the critical period (Fagiolini et al., 2003). In physiological conditions, 
GABAergic transmission matures later than glutamatergic circuits (Jiang et al., 2005). If 
GABAergic tone is precociously increased during development through infusion of benzodi-
azepines, overexpression of BDNF, exposure to environmental enrichment (EE) or removal of 
PSA-NCAM (polysialic acid presented by the neural cell adhesion molecule), the onset and 
closure of the critical period are accelerated (Hanover et al., 1999; Huang et al., 1999; Iwai et 
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al., 2003; Cancedda et al., 2004; Di Cristo et al., 2007. See Sale et al., 2010 for a comprehen-
sive review). 
 In the adult visual system, inhibitory circuitry stabilizes synaptic connections, thus re-
ducing neural plasticity: pharmacological reduction of GABAergic transmission reactivates 
OD plasticity in response to MD in adult rats (Harauzov et al., 2010), and several lines of evi-
dence demonstrate that inhibitory tone is reduced by manipulations that increase visual corti-
cal plasticity, such as EE (Sale et al., 2007; Baroncelli et al., 2010), dark rearing (He et al., 
2006) and fluoxetine treatment (Maya Vetencourt et al., 2008). Furthermore, GABA has been 
suggested to be crucial in masking existing horizontal connections and consequently in the 
rapid reorganization of cortical maps after, for instance, loss of afferents due to peripheral 
nerve transection or limb amputation (Jacobs and Donoghue, 1991; Chen et al., 1998; Wu and 
Kaas, 1999). 
!
Plasticity in the spinal cord 
As in other areas of the CNS, neuronal plasticity occurs in the spinal cord in response to expe-
rience through a variety of mechanisms. During development spinal cord plasticity is in-
volved in standard behaviors like locomotion and rapid withdrawal from pain (Waldenstrom 
et al., 2003), while in the adulthood plasticity contributes to the acquisition and maintenance 
of new motor skills (see Wolpaw, 2007 for an extensive review). Moreover, spinal cord plas-
ticity has a role in the mechanisms that lead to functional recovery (adaptive plasticity) or 
secondary adverse consequences (maladaptive plasticity) after an injury (Goldberger, 1977; 
Sanes and Donoghue, 2000; Blesch and Tuszynski, 2002; Raineteau et al., 2002; Edgerton et 
al., 2004). It has been estimated that if as little as 10–15% of the descending spinal tracts are 
spared, some locomotor function can recover (Basso, 2000; Metz et al., 2000). Based mostly 
on the results of studies using animal models, reorganization of the CNS, including synaptic 
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plasticity, axonal sprouting, and cellular proliferation, has long been known to spontaneously 
occur following spinal cord lesions. This reorganization occurs in the spinal cord circuitry and 
in supraspinal structures. 
 Early after SCI, in a time window varying between species, a certain degree of sponta-
neous recovery can occur (see Onifer et al., 2011 for a review). In this phase, the contribution 
of plasticity to functional return and recovery is difficult to discriminate from other possible 
processes including the recovery from spinal shock, a condition probably due to the break-
down of membrane potentials, excessive neurotransmitters levels, and the loss of neuromodu-
lators regulating the excitability in the spinal cord (as the 5HT mediated system) that leads to 
the loss of muscle tone and segmental spinal reflexes (Smith and Jeffery, 2005). The onset for 
return of spontaneous function in both humans and animals after SCI could be due to the 
restoration of motoneuron excitability by constitutive expression of 5HT2C receptors (Fouad 
et al., 2010; Murray et al., 2010), adaptations in polysynaptic flexor reflexes involved in lo-
comotor circuits (Lavrov et al., 2006; Dietz et al., 2009) and synaptic rearrangements 
(Rossignol, 2006). 
 As would also be expected, SCIs (both complete and incomplete) produce consider-
able reorganization in the spinal cord circuitry, with sprouting of collaterals from damaged 
fibers (regenerative sprouting) and sprouting of lesion-spared descending axons (compensato-
ry sprouting, Tuszynski and Steward, 2012). Several experiments showed the existence of re-
generative and compensatory sprouting by corticospinal tract axons (CSTs); for example, after 
cervical SCI in rats, spontaneous sprouting from the ventral CSTs occurred onto medial mo-
toneuron pools in the cervical spinal cord, leading to spontaneous recovery (Weidner et al., 
2001). Furthermore, Bareyre et al. reported that after incomplete spinal cord injury in rats, 
transected hindlimb CSTs sprouted into the cervical gray matter to contact short and long pro-
priospinal neurons (PSNs). Over 12 weeks, contacts with long PSNs that bridged the lesion 
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were maintained, whereas contacts with short PSNs that did not bridge the lesion were lost. In 
turn, long PSNs arborize on lumbar motor neurons, creating a new intraspinal circuit relaying 
cortical input to its original spinal targets (Bareyre et al., 2004). Similarly, in rhesus monkeys 
a C7 spinal cord hemisection led to marked spontaneous plasticity of CSTs, with reconstitu-
tion of 60% of pre-lesion axon density arising from sprouting of spinal cord midline-crossing 
axons, and this extensive anatomical recovery was associated with improvement in coordinat-
ed muscle recruitment, hand function and locomotion (Rosenzweig et al., 2010). Other de-
scending pathways, such as the neuromodulatory efferents, undergo anatomical plasticity after 
SCI. For example, compensatory plasticity of the rubrospinal tract was found to mediate the 
recovery of forepaw function following CST lesion in cats (Alstermark et al., 1987) and mon-
keys (Belhaj-Saif and Cheney, 2000). Similarly, rat cervical SCI led to increased sprouting of 
reticulospinal fibers rostral to the injury (Weishaupt et al., 2013), and several experiments 
showed that serotoninergic neurons sprout after spinal cord trauma (Sharma et al., 1990; In-
man and Steward, 2003; Camand et al., 2004); intriguingly, in a cortical model of lesion, sero-
toninergic neurons displayed lack of axonal dieback and enhanced sprouting within the in-
hibitory environment of the glial scar, probably thanks to significantly higher amounts of 
growth-associated protein-43 and/or β1 integrin than cortical neurons (Hawthorne et al., 
2011). 
 Some recovery of motor control after cord hemisection in cats has been attributed to 
collateral sprouting of primary afferent axons (Goldberger et al., 1993; Helgren and Gold-
berger, 1993), and early studies demonstrating enlarged excitatory postsynaptic potentials in 
chronic spinal cats attributed part of the increase to sprouting of primary afferent fibers (Nel-
son and Mendell, 1979). 
 In response to SCI, synaptic plasticity as well as anatomical reorganization can also 
occur at cortical and subcortical regions. Several studies have reported that cortical territories 
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controlling intact body parts tend to enlarge and invade cortical regions that have lost their 
peripheral target (McKinley et al., 1987; Jain et al., 1997; Fouad et al., 2001; Ghosh et al., 
2010). The underlying mechanisms are hypothesized to be similar to those mediating reorga-
nization after cortical injury, including disinhibition of latent cortical connections and axonal 
sprouting at multiple levels of the neuraxis (reviewed in Raineteau and Schwab, 2001; Fouad 
and Tse, 2008; Kaas et al., 2008). Another mechanism may be injury-induced structural plas-
ticity in the dendritic spines of cortical motoneurons, as suggested by the observation that in 
rodents, after cervical SCI, dendritic spine density and morphology in neurons of the motor 
cortex is modified over 3 days to 2 weeks (Kim et al., 2006). TMS studies in human SCI pa-
tients revealed motor reorganization, as muscles immediately rostral to the lesion could be 
activated through bigger regions of the cortex (Levy et al., 1990; Topka et al., 1991). On the 
other hand, PET, EEG and fMRI studies showed that appropriate (e.g. foot, leg) motor areas 
can be activated by imagined movements, even in long-term paraplegic or tetraplegic patients 
(Cohen et al., 1991; Corbetta et al., 2002; Curt et al., 2002; see Endo et al., 2009 for a 
review). 
 Besides underlying spontaneous recovery, neuroplasticity can also lead to detrimental 
consequences (Brown and Weaver, 2012). Increase in neuronal excitability due to products of 
microglial activation and changes in sodium channel and glutamate receptor expression 
(Deumens et al., 2008), collateral sprouting of calcitonin gene-related peptide (CGRP)-con-
taining primary afferent fibers (Christensen and Hulsebosch, 1997a; 1997b) and aberrant 
growth of descending serotoninergic axons in the spinal cord dorsal horn (Inman and Steward, 
2003) have been indicated as the main causes of neuropathic pain, a condition that leads to 
abnormal sensations (dysesthesia) or to the insurgence of nociception after a non-painful 
stimulus (allodynia). In addition, SCI is often associated with autonomic dysreflexia, an ab-
normality of blood pressure control characterized by extreme hypertension accompanied by a 
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pounding headache and slow heart rate (see Weaver et al., 2006 and Mathias, 2006 for re-
view): the entering of sensory input in the spinal cord below the level of the lesion leads to 
exaggerated sympathetic (autonomic) responses that can be associated with an increased 
CGRP-containing primary afferent arbor in the dorsal horn (Krenz and Weaver, 1998; Krenz 
et al., 1999), or in the presence of a normal arbor, with loss of descending inhibitory influ-
ences on spinal sympathetic reflexes (Gris et al., 2005). Moreover, modification in neuronal 
excitability after SCI can lead to the insurgence of spasticity, an involuntarily elevated muscu-
lar activity that can be triggered by a variety of sensory inputs, such as cutaneous stimulation 
(Norton et al., 2008). Notably, up-regulation of 5HT2 receptors and lowered expression of the 
potassium-chloride co-transporter KCC2 (which keeps Cl- intraneuronal concentration low) in 
motoneuron membranes have been shown to be involved in the generation of this phe-




Chapter 3: Experimental therapies for spinal cord injury 
In general, the spinal cord tries to repair itself after the initial insult: spontaneous recovery can 
be observed in animal models (Muir and Whishaw, 1999; Weidner et al., 2001; Fenrich and 
Rose, 2009; Rosenzweig et al., 2010) as well as in patients (Fawcett et al., 2006; Scivoletto et 
al., 2007). After injury, immediately early genes are overexpressed, recapitulating a situation 
typical of the developing nervous system (Maier and Schwab, 2006); signs of reorganization 
of neural circuits, for instance the appearance of regenerative or compensatory sprouting, 
have also been observed (Ramon y Cajal, 1928; Bradbury and McMahon, 2006). Some stud-
ies indicate that macrophages infiltrating the lesion site in the acute phase could contribute to 
neuroprotection (removal of cellular debris, release of protective cytokines) and to the reorga-
nization of damaged tissue in particular temporal contexts and in species/strain specific man-
ner, besides their well characterized pro-degenerative role (Schwartz, 2003; Donnelly and 
Popovich, 2008). 
 Acquired knowledge on processes that are occurring in acute, sub-acute and late phase 
of injury allowed researchers to develop and test various kinds of experimental therapies in 
the attempt to achieve axonal regeneration, remyelination of damaged axons and, in general, 
recovery of function. Some of these approaches have been demonstrated to be efficient in an-
imals models and reached the clinical trial phase. 
!
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Cell transplantation therapies 
The most evident anatomical consequence of spinal cord injury is the interruption of connec-
tions between the proximal and the distal segment of the spinal cord itself due to axon section 
and cell death; then, cell transplantation represent a promising strategy to replace damaged 
tissue, bridge the lesion cavity, counteract axonal demyelination and, moreover, can be used 
as a tool to create a neuroprotective and pro-regenerative environment for severed axons. 
!
Peripheral nerve grafts 
The first experiment of regeneration induced by cellular transplantation was carried out in 
1911 by Francisco Tello, who transplanted portions of peripheral nerves in rabbit cerebral cor-
tex and found out that cortical axons could enter in and elongate on the peripheral tissue (Tel-
lo, 1911). His pioneering work gave the basis for experiments with autologous peripheral 
nerve graft in injured spinal cord, which demonstrated that this treatment can induce axonal 
regrowth into the graft and functional improvement in rats with a complete spinal cord tran-
section, alone (Richardson et al., 1980; Cheng et al., 1996) or in combination with other ex-
perimental strategies (Lee et al., 2002; Levi et al., 2002; Tom and Houlé, 2008), with one case 
of partial functional recovery in a patient with a chronic thoracic injury (Cheng et al., 2004). 
 Today, cellular transplants are preferred to nerve bridges: single cells can be purified 
and expanded in vitro to reach the high amount of material required to fill the cystic cavity 
and, most importantly, cells can be manipulated to produce and release factors at the lesion 
site (Ramer et al., 2005). 
!
Schwann cells 
Several studies demonstrated that the part of the peripheral nerve that actually works on axon-
al regeneration is represented by Schwann cells (SCs): this cells, indeed, create a more per-
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missive environment after peripheral nerve injury by increasing the production of pro-prolif-
erative factors (as neurotrophins and cell adhesion molecules) and decreasing the expression 
of inhibitory myelin proteins (see Oudega and Xu, 2006 for a review); in addition, SCs can 
recreate the myelin sheath around severed and intact central axons (Gilmore, 1971). Schwann 
cells have been successfully implanted in the rat spinal cord and regrowth of axons into the 
bridge graft was observed; a recovery of function has also been reported in some studies (Xu 
et al., 1997; Xu et al., 1999; Bunge, 2002; Takami et al., 2002). Unfortunately, regenerating 
axons were not able to cross the graft tissue and to reinnervate the host, and SCs seem to be 
ineffective on corticospinal axon regeneration (Fehlings and Vawda, 2011). For these reasons, 
combinatorial strategies with treatments aimed to reduce environment inhibition (as glial scar 
digestion, Fouad et al., 2005) and to increase pro-regenerative factors (as neurotrophins and 
cell adhesion molecules, Xu et al., 1995; Lavdas et al., 2010) have been evaluated. Schwann 
cells were tested in a study on patients with a chronic mid-thoracic lesion (Saberi et al., 2008); 
the study demonstrated that SCs could be safe for humans, as no negative consequences of the 
implant were recorded, but the beneficial outcome of this treatment was not clear (only one 
patient had a better performance after the therapy, but it was not possible to assess if it was 
caused by transplanted cells or not). 
!
Olfactory ensheathing glia 
Olfactory ensheathing glia (OEG) are cells derived from embryonic and adult olfactory bulb 
important for maturation and migration of olfactory neurons; these cells share some character-
istics with SCs and astrocytes (Xu and Onifer, 2009), then they are considered a good tool to 
make a bridge between peripheral and central nervous systems. Olfactory glial cells have been 
tested in several injury models, giving encouraging results on regeneration of corticospinal 
axons and recovery of function in rats when used alone (Li et al., 1998, 2003; Ramon-Cueto 
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et al., 2000; Keyvan-Fouladi et al., 2003; Plant et al., 2003; López-Vales et al., 2007) or in 
combination with other treatments (Ruitenberg et al., 2003, 2005; Cao et al., 2004; Kubasak 
et al., 2008b); nevertheless, there have been cases in which a recovery was not observed 
(Takami et al., 2002; Ramer et al., 2004; Deumens et al., 2006; Lu et al., 2006; Bretzner et al., 
2008), underlining the necessity to establish the optimal conditions for OEGs transplantation 
to work, as cell source, age of cells and graft strategy (Thuret et al., 2006). To date, OEGs 
have been used in some clinical trials, with beneficial effects observed in chronic patients 
(Lima et al., 2006; 2010). 
!
Bone marrow stromal cells 
Bone marrow stromal cells (BMSCs) have been used in transplantation therapy for many dif-
ferent diseases; they can be easily isolated from bone marrow, constituting a minimally inva-
sive source for autologous cell transplantation; moreover, BMSCs have anti-inflammatory and 
immunomodulatory effects, mesodermal differentiation potential and secrete several neu-
rotrophic factors (Fehlings and Vawda, 2011). Even though there is no conclusive evidence 
about their capability to differentiate in neural or glial cells (Lu et al., 2004b), BMSCs have 
been used in experimental SCI therapy in rats (Urdzíková et al., 2006; Lu et al., 2007; 
Novikova et al., 2011) and non-human primates (Deng et al., 2006) with beneficial effects on 
locomotion and axonal regrowth. Anyway, there is great variability in results depending on 
cell source (age, donor, culture conditions; Neuhuber et al., 2005; Ruff et al., 2012). 
 Despite the lack of consistency from preclinical studies, there are ongoing clinical 
studies with autologous BM-derived cells on small patient cohorts. The few studies carried 
out so far demonstrated that BMSCs are safe for human application, but no clear amelioration 
above spontaneous recovery was observed in these patients (Callera and do Nascimento, 
2006; Chernykh et al., 2007; Yoon et al., 2007; Saito et al., 2008). 
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Neural progenitors 
Neural progenitor cells (NPCs) represent a source for reconstituting damaged circuits, re-
myelinating axons and increasing plasticity and/or axonal regeneration. They can be obtained 
from embryonic stem cells (eNPCs) or from adult stem cells (aNPCs).  
 Embryonic stem cells (ESCs) are obtained from the inner cell mass of the early blasto-
cyst; they can potentially differentiate in every cellular type of an organism and, moreover, 
can indefinitely proliferate in vitro maintaining their pluripotency (Richards et al., 2002; Ko et 
al., 2007). Embryonic stem cells can be expanded in vitro as neurospheres containing precur-
sors of neurons, astrocytes and oligodendrocytes, besides still pluripotent stem cells (Svend-
sen et al., 1999); studies on SCI models demonstrated that eNPCs transplantation resulted in 
migration of cells from injection site, differentiation in neurons, astrocytes and oligodendro-
cytes and improvement in function (McDonald et al., 1999; Ogawa et al., 2002; Meng et al., 
2008). Unfortunately, the use of ESCs is subjected to some major caveats, such as terato-
genicity in vivo (Fong et al., 2010), need to subject the host to immunosuppression before im-
plantation (ESC are allogenic) and ethical questions around the use of human embryos for 
clinical research. 
 Adult stem cells (ASCs) can be found in mammals in the periventricular sub-ependy-
mal layer and in the subgranular zone of the dentate gyrus of the hippocampus in the  brain 
and in the ependymal regions lining the central canal of the spinal cord (Hawryluk and 
Fehlings, 2008; Barnabé-Heider et al., 2010). They represent an autologous source of stem 
cells, then reducing ethical concerns about cellular transplantation and risk of rejection. As 
eNPCs, aNPCs can be expanded in vitro as neurospheres (Weiss et al., 1996; Shihabuddin et 
al., 1997), but differently from eNPCs, adult progenitors tend to remain undifferentiated or to 
differentiate principally in glia when transplanted in the adult nervous system (Cao et al., 
2001). Anyway, aNPCs can represent a good candidate for cellular therapy in humans, since 
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aNPCs transplantation induced functional recovery in experimental models of SCI (Karimi-
Abdolrezaee et al., 2006; Bottai et al., 2008; Parr et al., 2008; Moreno-Manzano et al., 2009).  
 Oligodendrocyte restricted progenitors (OPCs) constitute a very promising cellular 
type for SCI therapy (Blakemore et al., 2000). They can be obtained from NPCs or from en-
dogenous stem cells with the administration of particular transcription factors (as sonic 
hedgehog) and several growth factors expressed by the neural plate during development 
(Bambakidis et al., 2008). When transplanted in animal models of SCI, OPCs differentiated in 
mature oligodendrocytes, increased remyelination and promoted recovery of function (alone 
or in combination with viral vectors expressing neurotrophins, Cao et al., 2005; Keirstead et 
al., 2005). Human ESC derived OPCs were proposed for a phase I clinical study (by Geron 
Corporation, Menlo Park, CA) that is still underway. 
 In order to overcome the ethical questions regarding the use of ESCs and the limited 
availability of ASCs, scientists developed techniques to dedifferentiate somatic cells into in-
duced pluripotent stem cells (iPSC) (Nakagawa et al., 2008; Okita et al., 2008; Yamanaka, 
2010). The great advantage of these cells is that they are patient-specific, thus reducing reject 
risks; moreover, powerful reprogramming technologies have been developed to generate iPSC 
and differentiate them directly from skin or peripheral blood cells, avoiding the use of genetic 
and viral manipulations (Vierbuchen et al., 2010; Yamanaka, 2010). 
!
Autologous macrophages 
Since the observation that the inflammatory response differs in peripheral and central nervous 
systems after injury, a compromised recruitment of macrophages has been indicated as one of 
the causes of lack of regeneration in lesioned spinal cord (Hirschberg and Schwartz, 1995). To 
obviate to this defective response, an autologous transplant of activated macrophages was at-
tempted in a rat model of SCI: the transplant induced a partial recovery of function (assessed 
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both behaviorally and electrophysiologically) and the regeneration of axons beyond the lesion 
site (Rapalino et al., 1998). These positive results, together with the manageability of cellular 
preparations for transplant, led to the first clinical trial for cellular transplantation therapy 
(PROCORD, Proneuron Biotechnologies Inc.). The study enrolled 16 patients with clinically 
complete SCI; after the treatment, five patients showed amelioration toward an incomplete 
injury status (three patients became ASIA C, two patients became ASIA B). Moreover, no ad-
verse effect due to the transplantation was observed (Knoller et al., 2005). A phase II random-
ized multicenter trial was started but suddenly suspended for financial problems. 
 Conversely, the attempt to induce endogenous macrophages to be activated with mi-
croinjections of zymosan, a glucan prepared from yeast cell wall, induced detrimental effects 
on hindlimb function and tissue damage (Popovich et al., 2002). 
!
Gene therapy 
After injury, neurons display the expression of several growth associated genes, as the imme-
diate early genes L1, c-Jun and c-Fos and GAP-43 (43 kDa growth-associated protein, Jenk-
ins et al., 1993; Chaisuksunt et al., 2000), in a similar fashion to that appearing during devel-
opment. Unfortunately, after the initial intrinsic growth response, axons fail to regenerate 
(Maier and Schwab, 2006). One possible cause for this phenomenon could be the lack of 
trophic factors, whose levels decrease dramatically in the adult (Maisonpierre et al., 1990). 
For this reason the administration of growth factors, such as neurotrophins (NGF, BDNF, NT-
3, NT-4/5), cytokines (LIF, IL-6, CNTF), GDNF family ligands and insulin-like growth factor 
(IGF), represents a promising strategy to increase regeneration and plasticity after SCI. 
 The delivery of these molecules can be addressed directly by local injection at the site 
of injury (Schnell et al., 1994) or by intrathecal infusion with a catheter (Jakeman et al., 1998) 
or an osmotic minipump (Bradbury et al., 1999; Namiki et al., 2000). Otherwise, it is possible 
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to transduce cells - as fibroblasts (Jin et al., 2002), SCs (Weidner et al., 1999), BMSCs (Lu et 
al., 2005), OEGs (Cao et al., 2004), NPCs (Cao et al., 2005) - with viral vectors, such as ade-
no- and adeno-associated virus (AAV, Grieger and Samulski, 2012) and lentivirus (LV, Lund-
berg et al., 2008), containing genes encoding for growth factors and then graft these cells in 
the lesion site (Shumsky et al., 2003; Tobias et al., 2003; Tuszynski et al., 2003; Blesch et al., 
2004; Mitsui, 2005; Sasaki et al., 2009). These vectors can also be used to directly infect the 
CNS in vivo: they can be transported retrogradely in the neurons and integrate in the host 
genome, producing a long lasting and stable over-expression of the desired gene in the infect-
ed cells (Liu et al., 1997; Romero and Smith, 1998; Blits and Bunge, 2006; Taylor et al., 
2006a; Kwon et al., 2007). The regulation of delivered genes in the injured spinal cord is an 
important issue: the constitutive expression of trophic factors within the lesion site could, for 
instance, enhance the axonal growth into the graft while preventing their elongation beyond 
the graft itself. Moreover, the availability of growth promoting molecules for an indefinite 
time might cause the massive infiltration of Schwann cells in the lesion site, leading to in-
creasing graft size (Blesch and Tuszynski, 2003; Blesch et al., 2004). 
 Concerning the molecules evaluated so far, neurotrophins appear to have a differential 
effect on different circuits in the spinal cord, consistent with the distribution of their respec-
tive receptors: NGF (nerve growth factor) promotes the sprouting and regeneration of cholin-
ergic local motor, primary nociceptive sensory and coerulospinal axons (Tuszynski et al., 
1994; Grill et al., 1997b; Romero and Smith, 1998). Adenoviral gene transfer of NGF to the 
dorsal spinal cord can also induce directed sensory axon regrowth across the dorsal root entry 
zone into the spinal cord (Romero et al., 2001). One of the major caveats linked with the use 
of NGF is the induction of severe hyperalgesia due to the effect on nociceptive fibers 
(Romero et al., 2000). In order to restrict sensory axon regeneration to their appropriate tar-
gets, NGF gene transfer to the superficial layers of the spinal cord was combined with a re-
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pulsive signal for axon growth (semaphorin 3A) into deeper layers (Tang et al., 2004a, 2007): 
this strategy allowed to limit the expression of NGF in the ventral cord, thus limiting the pen-
etration of nociceptive fibers in this region and reducing pain. 
 BDNF acts on the regeneration of raphespinal, coerulospinal, rubrospinal, reticu-
lospinal, vestibulospinal, local motor and proprioceptive sensory axons (Kobayashi et al., 
1997; Liu et al., 1999; Jin et al., 2002; Kwon et al., 2002; Ruitenberg et al., 2004; Lu et al., 
2005). The regrowth has been associated with the increase of the expression of regeneration-
associated genes such as GAP-43 and βIII-tubulin (Kobayashi et al., 1997; Ruitenberg et al., 
2004; Kwon et al., 2007). Concerning CST fibers, instead, BDNF administration fails to in-
duce sprouting or regeneration of lesioned axons (Lu et al., 2001; Brock et al., 2010), also if it 
enhances the survival of corticospinal neurons when delivered both in the cortex (near the cell 
soma ) or in the spinal cord (Giehl and Tetzlaff, 1996; Lu et al., 2001; Brock et al., 2010).  
 Similar to BDNF, NT-3 expression enhances the regenerative response of raphespinal 
and proprioceptive sensory axons (Bradbury et al., 1999; Taylor et al., 2006b; Alto et al., 
2009). Moreover, sprouting and regeneration of CST axons has been observed after NT-3 de-
livery (Schnell et al., 1994; Grill et al., 1997a; Blits et al., 2000; Tuszynski et al., 2003; Fortun 
et al., 2009), also if it is ineffective to protect CST neurons from lesion-induced atrophy 
(Brock et al., 2010). This differential effect of BDNF and NT-3 on CST somata and axons can 
be explained with the differential signaling and retrograde transport of their respective recep-
tors (trkB and trkC) from the axonal compartment to the soma (Franz et al., 2012). 
 NT-4 acts on raphespinal, rubrospinal, reticulospinal, coerulospinal and propriospinal 
sensory axons (Bregman et al., 1997; Kobayashi et al., 1997; Blesch et al., 2004); this neu-
rotrophin increases branching into cell grafts, also if growth beyond transplanted tissue has 
not been observed.  
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 GDNF induces growth of motor and dorsal column sensory axons after partial and 
complete spinal cord transections and induces remyelination; moreover, it ameliorates neu-
ronal atrophy of CST motor neurons after injury (Bennett et al., 1998; Blesch and Tuszynski, 
2003; Tang et al., 2004b). 
 IGF-I gene transfer supports CST neuron survival but, despite its essential role during 
CST development (Ozdinler and Macklis, 2006), fails to promote axonal regeneration in the 
adult injured spinal cord (Hollis et al., 2009b). 
 Until now, no clinical trial for gene therapy in human SCI has been attempted. A study 
carried out to treat Alzheimer’s disease showed that the intracerebroventricular infusion of 
NGF induced pain and weight loss in patients during the course of treatment, leading to the 
stop of the trial (Eriksdotter Jönhagen et al., 1998). A more detailed knowledge about safety 
of transgene expression and regulation is still needed before translating the pre-clinical, en-
couraging results to humans. 
!
Pharmacological therapies 
Pharmacological therapies are meant to act on different aspects of SCI pathophysiology: 
avoid secondary damage (acute neuroprotective treatments), reestablish signal transduction, 




The most studied molecule in acute SCI therapy is methylprednisolone sodium succinate 
(MPSS), a drug belonging to the glucocorticoid class. Studies in animal models of acute SCI 
demonstrated that MPSS was neuroprotective when it was administered in high doses 
(Braughler and Hall, 1984; Braughler et al., 1987; Oudega et al., 1999). The neuroprotective 
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effect could be explained by MPSS antioxidant action through inhibition of lipid peroxidation 
and ΤΝFα (that leads to modulation of the inflammatory/immune cells response), improved 
vascular perfusion and prevention of calcium influx and accumulation (Hall, 1992). The effi-
cacy of MPSS was evaluated in three large scale acute clinical trials, named NASCIS (Na-
tional Acute Spinal Cord Injury Studies) I, II and III (Bracken et al., 1985; 1990; 1992; 1997; 
1998). The results emerged form these studies highlighted that MPSS exerted some neurolog-
ical benefit when administered in high doses within the very acute phase of SCI (8 hours since 
the first insult), leading to the use of corticosteroids as a standard care for acute SCI patients. 
Further analysis of the clinical trial results showed that functional improvements were modest 
and present only in a small cohort of patients; moreover, increased rates of gastrointestinal 
hemorrhage, sepsis, pneumonia, delayed wound healing, and death due to respiratory compli-
cations were observed (Hurlbert, 2000; Bydon et al., 2013). Nevertheless, due to lack of alter-
native therapies, MPSS is still considered for use to treat acute SCI (Hawryluk et al., 2008).  
 Minocycline, a second-generation tetracycline antibiotic commonly used in dermatol-
ogy, has been demonstrated to be beneficial in neurodegenerative conditions in which in-
flammation plays a major role, such as stroke, Parkinson’s disease, Huntington’s disease, 
amyotrophic lateral sclerosis and multiple sclerosis (Yong et al., 2004). In experimental mod-
els of SCI the systemic administration of minocycline inhibited microglial activation, reduced 
delayed oligodendrocyte death and attenuated axonal dieback (Stirling et al., 2004; Festoff et 
al., 2006; Yune et al., 2007), promoting functional recovery in mice and rats (Lee et al., 2003; 
Wells et al., 2003; Stirling et al., 2004; Teng et al., 2004). The promising data obtained from 
preclinical analysis led to a clinical trial from the University of Calgary. The study reached 
phase II and demonstrated that intravenous injections of minocycline were feasible and safe 
for patients with an acute, complete SCI; also if the results showed a tendency towards im-
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provement in treated patients vs placebo, however, no clear functional recovery was observed 
(Casha et al., 2012).  
 In vivo and in vitro studies demonstrated that gangliosides, glycosphingolipids con-
taining sialic acid that are abundantly expressed in the CNS, could mimic or at least increase 
the action of neurotrophic factors, thus enhancing neurite outgrowth and plasticity and reduc-
ing excitotoxicity and apoptotic cell death (Ferrari and Greene, 1998). A particular kind of 
ganglioside, the monosialotetrahexosylganglioside (GM-1 or Sygen, Fidia Pharmaceutical 
Corporation, Washington, DC) has been proven to induce neuroprotection and functional re-
covery when administered in an experimental model of SCI (Bose et al., 1986). The first clin-
ical trial for GM-1 in acute SCI (the prospective randomized Maryland GM-1 study, enrolling 
37 patients) showed that the GM-1 administration promoted a significant amelioration in the 
ASIA motor score (Geisler et al., 1991). The results led to the Sygen Multi-Center Acute 
Spinal Cord Injury Study, enrolling more than 750 patients. In this study GM-1 was adminis-
tered after MPSS (along the NASCIS II protocol) because of ethical reasons (at that time clin-
icians believed that MPSS was safe and efficient, so all patients received it). Unfortunately, 
the functional outcome measured at the end of the trial evaluation (26 weeks after SCI) did 
not differ between GM-1 and placebo groups, also if a positive trend and a faster amelioration 
of sensitive and motor functionality was observed in GM-1 patients, in particular in those 
with incomplete SCI (Geisler et al., 2001). 
 Thyrotropin releasing hormone (TRH) is a tripeptide involved in the regulation of an-
terior pituitary gland function. The application of TRH induced neurological recovery in ex-
perimental SCI models in a dose-dependent fashion (Faden et al., 1984; Takami et al., 1991), 
indeed TRH antagonizes secondary injury effectors such as platelet activating factor, excito-
toxic amino acids, endogenous opioids and peptidoleukotrienes (Dumont et al., 2001). The 
only clinical trial completed so far showed that the TRH induced a significant recovery of 
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function in case of incomplete SCI, whereas it was ineffective in complete lesions (Pitts et al., 
1995). 
 Since the observation that endogenous opioids rise after SCI and participate to the 
acute phases of pathophysiology (Holaday and Faden, 1980; Krumins and Faden, 1986; Long 
et al., 1987; McIntosh et al., 1987), the use of opioid receptor antagonists has been investigat-
ed in experimental SCI models. These studies demonstrated that naloxone, a non specific opi-
oid receptor antagonist, could increase sensorimotor recovery and prevent post-traumatic is-
chemia in several models of SCI (Young et al., 1981; Faden et al., 1984; Winkler et al., 1994). 
Regardless some discrepancies in preclinical data (Wallace and Tator, 1986; Haghighi and 
Chehrazi, 1987), naloxone was assessed for human therapy in a phase I clinical trial (Flamm 
et al., 1985) and as one of the treatment evaluated in NASCIS II (Bracken et al., 1990, 1992). 
The authors concluded that the use of naloxone could be beneficial for the treatment of in-
complete SCI, but further analysis should be addressed to clarify drug dosage and administra-
tion timing (Bracken and Holford, 1993). 
 More results from neuroprotective treatment studies are summarized in Table 2.  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Drug Molecular mechanism Preclinical studies Clinical trials
21-Aminosteroids 
(Tirilizad mesylate)
Antioxidant without a 
glucocorticoid effect
Functional recovery in cats (Anderson 
et al., 1988, 1991; Hall et al., 1989) 
and rats (Holtz and Gerdin, 1992); 
reversal of ischemia (Hall, 1988).
NASCIS III: effectiveness similar to 
MPSS, no adverse secondary effect 
(Bracken et al., 1997; 1998), but the 





(inibition of T-cell 
activation)
Dampened inflammatory response, 
improved locomotor score in rats 
(Madsen et al., 1998; López-Vales et 
al., 2005), increased oligodendrocytes 
survival (Nottingham et al., 2002), 
sprouting of ascending (Bavetta et al., 
1999) and descending fibers (Voda et 
al., 2005).
A clinical trial for the effectiveness of 
a combination of tacrolimus and 
minocycline on acute SCI is 
underway at the Riyadh Armed 




Reduction of apoptosis, 
decreased oxidation, 
decreased inflammatory 
processes, and decreased 
autoregulatory vascular 
response 
Improved motor function, decreased 
lesion severity in rats (Keswani et al., 
2004; Vitellaro-Zuccarello et al., 
2007; 2008). Other studies did not 
confirm neuroprotection (Mann et al., 
2008; Pinzon et al., 2008).
Evaluation of Tolerability and 
Efficacy of Erythropoietin (EPO) 
Treatment in Spinal Shock: 
Comparative Study Versus 
Methylprednisolone (MP) (Italy). 
Suspended. 
Erythropoietin Spinal Cord 
Compression Randomized Trial 
(Canada), terminated for insufficient 
accrual
Anti-CD11d Dampened neutrophil 
invasion 
Improved motor score in rats, less 
allodynia and dysreflexia (Taoka et 
al., 1997; Gris et al., 2004; Oatway et 
al., 2005; Bao et al., 2008; Fleming et 
al., 2008); depletion of early 
neutrophils is detrimental in mice 





Block of TNFα-mediated 
inflammatory response
Reduction of inflammation and 
apoptosis and improved motor 
performance in mice (Genovese et al., 
2006; 2008); reduction of neuropathic 
pain and lipid peroxidation in rats 




Table 2. Neuroprotective treatments. 
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Channel blockers 
Ionic unbalance is one of the most important features of acute SCI pathophysiology (see 
above).  
 Riluzole (or Rilutek - Sanofi Aventis) is a benzothiazole Na+ channel blocker; besides 
this principal effect, riluzole also inhibits presynaptic Ca2+dependent glutamate release (Wang 
et al., 2004). Systemic administration of riluzole exerted neuroprotective properties by sparing 
gray and white matter in rostrocaudal regions surrounding the injury epicenter in rat models 
(Schwartz and Fehlings, 2001; Ates et al., 2007), alone or in combination with MPSS (Mu et 
al., 2000); moreover, regrowth of sensory axons has been observed in in vitro preparations 
(Shortland et al., 2006). Considering the promising experimental results and the knowledge 
deriving from the use of riluzole for ALS therapy (Miller et al., 2012), two clinical trials have 
been planned to assess safety and efficacy of riluzole treatment in acute SCI (ClinicalTrials.-
gov Identifier: NCT00876889 and NCT01597518). 
 Glutamate level rises rapidly after CNS injury; the consequent overstimulation of 
NMDA receptors can lead to a massive influx of calcium that in turn can provoke axonal in-
jury and apoptotic or necrotic cell death through the activation of enzymes, mitochondrial 




antioxidant. Preservation of 
blood brain barrier 
integrity
Improved rat open field locomotor 
score (Pannu et al., 2005; 2007), 
reduction of apoptosis (Déry et al., 
2009). Other studies showed a 
dampened astroglial response, but 
little motor recovery (Holmberg et al., 
2008; Mann et al., 2010).
None
Drug Molecular mechanism Preclinical studies Clinical trials
!43
for the maintenance of vascular smooth muscle physiology (Liu et al., 2011). Preclinical stud-
ies showed that administration of nimodipine, a member of the dihydropyridine class of Ca2+ 
channel blockers, could increase spinal cord blood flow (Guha et al., 1985) and reverse is-
chemic hypoperfusion (Fehlings et al., 1989), even though these results were not replicated by 
other groups (Ford and Malm, 1985; Haghighi et al., 1993). A clinical trial conducted in 
France failed to demonstrate the efficacy of nimodipine in SCI patients (Pointillart et al., 
2000). Conversely, gacyclidine (GK-11, Beaufour-Ipsen Pharma), a non competitive NMDA 
receptor antagonist, improved function, histology, and electrophysiology in a rat model of SCI 
(Hirbec et al., 2001). In addition, GK-11 was substantially less neurotoxic than other NMDA 
antagonists (Gaviria et al., 2000), making it feasible for human application. A double-blind 
Phase II clinical trial was completed in France on 200 patients (Tadie et al., 1999) ; despite 
promising preliminary results, one year post injury analysis revealed a non significant trend 
toward improved function in treated patients, then GK-11 was no longer investigated as a 
therapeutic agent for SCI (Hawryluk et al., 2008). 
 Magnesium is an endogenous voltage-dependent blocker of NMDA receptors; more-
over, Mg2+ blocks voltage-gated calcium channels, and improves vascular perfusion by in-
hibiting vasoconstriction (Vink and Cernak, 2000). Since Mg2+ levels decrease significantly 
within the injured spinal cord (Lemke and Faden, 1990) and brain (Vink et al., 1987), its ex-
ogenous application has been proposed for SCI cure. Different studies reported that Mg2+ im-
proved biochemical, physiological, histological, and locomotor parameters after experimental 
injury (Süzer et al., 1999; Kaptanoglu et al., 2003a, b; Solaroglu et al., 2005; Wiseman et al., 
2009), but the high dosage failed to reach the safety requirements for human therapy (Temkin 
et al., 2007). Recently, further analysis showed that a lower Mg2+ dose combined with poly-
ethylene glycol (Medtronic, Inc) enhanced long-term clinical outcomes after SCI in rats (Di-
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tor et al., 2007). A Phase II multicenter study on human SCI patients is currently being orga-
nized by Medtronic (Kwon et al., 2010a). 
 The demyelination phenomenon caused by SCI exposes fast voltage-gated K+ chan-
nels at the internodal regions (Nashmi and Fehlings, 2001). The increased activity of K+ 
channels results in the shunting of Na+ current, short-circuiting of depolarization, and inhibi-
tion of the genesis of action potentials (Liu et al., 2011), thus provoking conduction failure. In 
vitro studies demonstrated that 4-aminopyridine (4-AP), a fast K+ channel blocker, induces 
the increase of action potentials conduction in models of chronic SCI (Shi and Blight, 1997; 
Jensen and Shi, 2003). Since the preliminary study conducted in 1993 by Hansenbout and 
coworkers on 8 patients with an incomplete chronic SCI (Hansebout et al., 1993), various 
clinical evaluations showed that 4-AP can ameliorate motor and sensory function below in-
jury site (Wolfe et al., 2001; Grijalva et al., 2003), while other studies failed to achieve func-
tional benefits (van der Bruggen et al., 2001; DeForge et al., 2004). Additional research is 
aimed to identify K+ blockers with greater affinity; recently, the novel K+ channel blocker 4-
AP-3-MeOH has been evaluated as an alternative choice for the reversal of conduction block 
in experimental SCI (Sun et al., 2010).  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Modulators of myelin associated inhibitors 
Figure 4. Growth inhibitors in the CNS. Abbreviations: CSPGs, chondroitin sulfate proteoglycans; ECM, extra-
cellular matrix; GPI, glycosylphosphatidylinositol; MAG, myelin associated glycoprotein; NgR1, Nogo-Recept-
or-1; OMgp, oligodendrocyte myelin glycoprotein; PirB, Paired- Immunoglobulin-like Receptor; PTPσ, Protein-
Tyrosine-Phosphatase-σ; TROY, TNFα orphan receptor (from Akbik et al., 2012). 
!
The inhibitory effect of white matter toward regeneration in the CNS was originally proposed 
by Ramon y Cajal in 1911. The direct experimental evidence was later provided by Schwab 
and colleagues who showed that CNS myelin, but not PNS myelin, possesses potent neurite 
growth inhibitory activity (Berry, 1982; Carbonetto et al., 1987; Caroni and Schwab, 1988; 
Crutcher, 1989; Savio and Schwab, 1989). Further research allowed to identify various 
myelin-derived inhibitory proteins (see Harel and Strittmatter, 2006 and Lee and Zheng, 2012 
for a review); in particular, three molecules have been studied in deep in relation with CNS 
degeneration: myelin-associated glycoprotein (MAG, McKerracher et al., 1994; Mukhopad-
hyay et al., 1994), oligodendrocyte myelin glycoprotein (OMgp, Mikol and Stefansson, 1988; 
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Wang et al., 2002b) and Nogo-A (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 
2000).  
 Myelin associated glycoprotein is expressed by oligodendrocytes in the periaxonal 
layer of myelin during the first phases of axonal myelin ensheathment and persists in a strictly 
periaxonal distribution, suggesting a stabilizing glial-axonal interaction (Bartsch et al. 1989; 
Trapp 1990). Myelin associated glycoprotein is known to have a dual role in axon growth de-
pending on the developmental stage of the neurons studied: growth promoting on younger 
neurons while growth inhibitory on older neurons, with this transition occurring at or soon 
after birth (Mukhopadhyay et al. 1994). Recombinant MAG potently inhibits neuronal cul-
tures in vitro, and this inhibition is rescued by immunodepletion of MAG (McKerracher et al. 
1994; Mukhopadhyay et al. 1994). 
 Originally isolated from CNS myelin, OMgp is detectable on membranes of several 
neuronal types, oligodendrocytes, and periaxonal myelin (Habib et al., 1998; Huang et al., 
2005). Recombinant OMgp potently inhibits neurite outgrowth of cerebellar granule neuron 
cultures and induces growth cone collapse in adult dorsal root ganglion cell cultures (Kottis et 
al., 2002; Wang et al., 2002b). 
 Nogo (or Rtn4) is a membrane protein belonging to the Reticulon family. Although 
Nogo exists in three different isoforms (A, B, and C), Nogo-A is the principle one, and its ex-
pression in the CNS, but not in the PNS (Huber et al., 2002; Wang et al., 2002c), suggests that 
Nogo-A may account for limited CNS regeneration. Nogo-A is highly expressed by neurons 
during development, while in the adult mammalian CNS it is found mainly in oligodendro-
cytes (Josephson et al., 2001; Huber et al., 2002; Wang et al., 2002c). Nogo-A has two main 
inhibitory domains: amino-Nogo, which is unique to the Nogo-A specific N-terminus, and 
Nogo-66, a 66-amino-acid loop which is common to all three isoforms (GrandPre et al., 
2000). Nogo-A has been repeatedly shown to initiate growth cone collapse and inhibit neurite 
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outgrowth in vitro by a wide number of laboratories (Chen et al., 2000; GrandPre et al., 2000; 
Prinjha et al., 2000; Wang et al., 2002c), and to limit regeneration of the CST after spinal cord 
injury in mammalian animal models (Schnell and Schwab, 1990; Bregman et al., 1995; Fouad 
et al., 2004). 
 The identification of Nogo-A and the description of Nogo-66 inhibitory fragment led 
to the discovery of Nogo Receptor-1 (NgR1), a GPI-linked leucine rich repeat protein 
(Fournier et al., 2001). Interestingly, NgR1 constitutes a common receptor for Nogo-A, MAG 
and OMgp, despite the lack of homology in their sequences (Liu et al., 2002; Wang et al., 
2002b). To initiate intracellular signal transduction, NgR1 requires the interaction with a 
membrane associate co-receptor (see Figure 4Figure 5), such as the low-affinity neurotrophin 
receptor p75 (Wang et al., 2002a), LINGO-1 (Mi et al., 2004) or TNFα orphan receptor 
TROY (Park et al., 2005). Moreover, in a screen for novel receptors for Nogo-66, Atwal and 
colleagues identified Paired Immunoglobulin-like Receptor B (PirB) as a high affinity recep-
tor for Nogo-66, MAG, and OMgp (Atwal et al., 2008). Activation of NgR1 and signaling 
through its co-receptors leads to increased activation of the small GTPase RhoA and its effec-
tors ROCK and LIMK1 (Fournier et al., 2003; Hsieh et al., 2006; Montani et al., 2009), while 
it reduces Rac1 activity (Niederost et al., 2002). These signaling cascades result in growth 
cone collapse and neurite outgrowth inhibition through modulation of actin polymerization, as 
seen in in vitro and in vivo models (Chen et al., 2000; GrandPre et al., 2000; Prinjha et al., 
2000). 
 The first strategy developed to counteract Nogo-A inhibitory effect consisted in the 
use of IN-1, an antibody raised against the myelin fraction containing Nogo-A (Caroni and 
Schwab, 1988). Afterwords, two new IgG anti-Nogo-A antibodies were developed (Buffo et 
al., 2000; Wiessner et al., 2003). The blockade of Nogo-A signaling with specific anti-Nogo-A 
antibodies enhanced regenerative CST sprouting and long-distance elongation in several 
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models of SCI; moreover, animals showed a remarkable functional recovery after treatment 
(Schnell and Schwab, 1990; Bregman et al., 1995; Thallmair et al., 1998; Brosamle et al., 
2000; Raineteau et al., 2001; Fouad et al., 2004; Freund et al., 2006). Very similar results 
were obtained through the inactivation of Nogo-A by intrathecal infusion of a soluble decoy 
receptor, NgR(310)ecto-Fc (Fournier et al., 2002; Li et al., 2004; Robak et al., 2009) or by 
blocking NgR with NEP1-40, an antagonistically active Nogo fragment competitive for 
Nogo-66 binding site (GrandPre et al., 2002; Li and Strittmatter, 2003). In addition, blockade 
of NgR1 co-receptor LINGO-1 in rats promoted sprouting of both rubrospinal and corti-
cospinal axons and improved functional recovery after SCI (Ji et al., 2006).  
 In 2006, Novartis sponsored the initiation of a multicenter, nonrandomized human 
clinical trial in Germany, Switzerland and Canada (ClinicalTrials.gov Identifier: NC-
T00406016) for the intrathecal infusion of the anti-Nogo-A antibody ATI355. In Phase I more 
than 50 acute ASIA A paraplegic or tetraplegic patients were enrolled to estimate safety, dos-
ing, tolerance and pharmacokinetics; so far, no deleterious side effects were observed. A 
Phase II has been planned to evaluate the effects of acute treatment before the beginning of 
therapeutic rehabilitation (Starkey and Schwab, 2012). 
 A different strategy to promote axonal sprouting and recovery after CNS injury con-
sists in the modulation of the Rac/Rho pathway, which has been found to constitute the com-
mon intracellular signaling cascade for the various myelin associated inhibitors (Figure 4). 
The application of Rho-A (the C3 transferase) or ROCK (the Y27632) inhibitors in the lesion 
site has been demonstrated to be neuroprotective (Rho activation contributes to apoptosis after 
neural damage) and to improve the behavioral outcome in partially transected mice (Dergham 
et al., 2002; Dubreuil et al., 2003; McKerracher and Higuchi, 2006; Dubreuil et al. 2003; 
McKerracher et al. 2006). Cethrin, a more cell-permeable version of C3, has been evaluated 
in two clinical trials in North America and Europe. The first study, sponsored by BioAxone 
!49
Therapeutic Inc., enrolled 37 ASIA A thoracic and cervical SCI patients that were treated with 
Cethrin within 7 days of their injury. The Phase II was concluded in 2007 and preliminary re-
sults suggest that part of patients experienced a partially recovery without major adverse ef-
fects (Kwon et al., 2010b). The second trial, promoted by Alseres Pharmaceuticals Inc., was a 
multicenter, randomized, double-blind, placebo-controlled, Phase II study and included adult 
patients with acute cervical SCI who received Cethrin within 72 hours from injury (Clinical-
Trials.gov Identifier: NCT00610337). Recently, it has been demonstrated that some non-
steroidal anti-inflammatory drugs like ibuprofen and indomethacin inhibit the Rho-A signal-
ing pathway in vitro and in vivo (Zhou et al., 2003); moreover, these drugs promoted axonal 
regeneration and locomotor recovery via RhoA inhibition in rats subjected to SCI (Fu et al., 
2007). Since these compounds are already widely used as pain relievers, they are likely to be 
transferred to human clinical trials for SCI therapy. 
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Targeting the Glial Scar 
After SCI, activated hypertrophic glia forms the glial scar and produces high amounts of 
ECM molecules, which reinforce the scar structure. Chondroitin sulphate proteoglycans 
(CSPGs) are a class of inhibitory ECM molecules (aggrecan, brevican, neurocan, versican, 
phosphacan and NG2) characterized by a core protein covalently linked to linear chondroitin 
sulfate glycosaminoglycan chains (CS-GAGs) (Kjellen and Lindahl, 1991; Morgenstern et al., 
2002). Chondroitin sulphate proteoglycan expression is important for the stabilization of 
synaptic connections in the CNS (Bartus et al., 2012): as the CNS matures and target innerva-
tion occurs, CSPG levels become down-regulated; conversely, their expression increases in 
areas where they are required for synaptic stability, forming lattice-like ECM structures called 
perineuronal nets (PNNs) around neuronal cell bodies and dendrites (Celio et al., 1998). Per-
ineuronal nets maturation peaks in concomitance with the end of the critical period and the 
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reduction of spine dynamics; besides, PNNs expression appears to be restricted to GABA-ex-
pressing neurons (Hartig et al., 1992; Hensch, 2005). 
 The glial scar represents a physical barrier to axonal regeneration; moreover, CSPGs 
inhibit the regenerative response through the Rho-ROCK signaling pathway (Borisoff et al., 
2003; Sivasankaran et al., 2004; Koprivica et al., 2005) and the CSPGs receptor PTPσ (trans-
membrane protein tyrosine phosphatase sigma, Shen et al., 2009). Chondroitinase ABC 
(ChABC) is a bacterial enzyme which cleaves CS-GAG chains from the CSPG core protein 
(Suzuki et al., 1968; Yamagata et al., 1968). The application of ChABC in in vitro prepara-
tions demonstrated that the liberation of CS-GAG chains allows neurite outgrowth on tissues 
rich in CSPGs such as injury-induced gliotic cortical tissue or adult spinal cord slices (McK-
eon et al., 1995; Zuo et al., 1998). ChABC infusion in experimental animals digested scar tis-
sue in the injured brain (Moon et al., 2001) and spinal cord (Lemons et al., 1999), and induced 
regeneration of lesioned axon (Moon et al., 2001; Bradbury et al., 2002). Since then, a lot of 
studies demonstrated that ChABC application is able to induce functional recovery in SCI 
models inducing the regeneration of injured fibers and the remodeling of injured and lesion-
spared axons, alone (Bradbury et al., 2002; Caggiano et al., 2005; Barritt et al., 2006; Massey 
et al., 2006; Garcia-Alias et al., 2008; Tester and Howland, 2008; Starkey et al., 2012) or in 
combination with other treatments (Yick et al., 2004; Fouad et al., 2005; Houle et al., 2006; 
Massey et al., 2008; García-Alías et al., 2009, 2011; Tom et al., 2009; Karimi-Abdolrezaee et 
al., 2010, 2012). 
 Alternative strategies to counteract the inhibitory effects of the glial scar are based on 
the reduction of CSPG deposition (Logan et al., 1999; Davies et al., 2004; Minor et al., 2008; 
Fujiyoshi et al., 2010), the inhibition of CS chains glycosilation (Grimpe and Silver, 2004; 
Grimpe et al., 2005; Hurtado et al., 2008), the blockade of CS motifs responsible for CSPG-
neuron interaction (Gama et al., 2006; Tully et al., 2006; Shen et al., 2009; Ohtake-Niimi et 
!51
al., 2010; Coles et al., 2011), or the modulation of CSPG signaling cascade, such as PTPσ 
knock-out (Shen et al., 2009; Fry et al., 2010) and Rho-ROCK pathway perturbation 
(Dergham et al., 2002; Sivasankaran et al., 2004; Koprivica et al., 2005; Lingor et al., 2007). 
 However, the glial scar constitutes also a protection from the spread of cellular dam-
age, infections and infiltration of non-CNS constituents (Fitch et al., 1999; Myer et al., 2006). 
Matrix metalloproteinases (MMPs), which degrade extracellular matrix and proteins (Stern-
licht and Werb, 2001) are up-regulated after SCI (Wells et al., 2003; Fleming et al., 2006; 
Buss et al., 2007), thus inducing an increase in blood brain barrier permeability. The genetic 
deletion of MMP-12 and MMP-9 allowed the recovery of function in a mouse model of SCI 
(Noble et al., 2002), indicating MMPs as a possible target for future therapies. 
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Modulation of intrinsic regenerative response 
A powerful approach to enhance the effects of growth promoting molecules in the injured 
spinal cord consists in the induction of intrinsic regenerative response of damaged neurons. 
For instance, the association of subcortical BDNF-secreting grafts with the overexpression of 
trkB receptor in CST neurons has been showed to be effective in the induction of axonal re-
growth into the transplanted tissue via the activation of the ERK pathway (Hollis et al., 2009a, 
Figure 4). Intrinsic response can be enhanced by gene transfer of transcription factors, like the 
cAMP response element binding protein (CREB, Gao et al., 2004), the activating transcription 
factor 3 (ATF3, Seijffers et al., 2007), or the signal transducer and activator of transcription 3 
(STAT3, Qiu et al. 2005), or proteins important during CNS development such as retinoic acid 
receptor beta (RARβ, Wong et al., 2006; Yip et al., 2006) and neuronal calcium sensor-1 
(NCS1, Yip et al., 2010). A particular case is represented by dorsal root ganglion neurons: the 
application of a “conditioning lesion” to the peripheral branch of sensory neurons leads to 
rapid and sustained changes in gene expression such as upregulation of cAMP signaling 
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pathways (Richardson and Issa, 1984; Neumann et al., 2002; Qiu et al., 2002; Lu et al., 
2004c) and cytokines (Cafferty et al., 2004; Cao et al., 2006), and these changes are translated 
in increased axonal regeneration. Besides, the effectiveness of conditioning lesion has been 
validated in acute as well as chronic spinal cord injuries (Kadoya et al., 2009), confirming that 
sensory axons retain the ability to respond to regenerative stimuli. 
 The effect of intracellular cAMP elevation can be achieved through indirects methods. 
Forskolin, an adenyl cyclase activator, stimulated nerve regeneration in transected sciatic 
nerve in vivo (Kilmer and Carlsen, 1984). Injection of a cAMP homologue, dbcAMP, induced 
increased regeneration of spinal axons in in vitro and in vivo models (Neumann et al., 2002; 
Qiu et al., 2002; Lu et al., 2004c). Rolipram, an inhibitor of phosphodiesterase 4 (PDE4, a 
degrading enzyme of cAMP, Krause and Kuhne, 1988), increased 5HT axon regeneration, re-
duced astrogliosis and induced functional recovery in rats subjected to SCI and cell trans-
plants (Nikulina et al., 2004; Pearse et al., 2004). Intriguingly, rolipram is able to cross the 
blood brain barrier, then it can be delivered orally or subcutaneously, making it a good candi-
date for use in patients  
!
Modulation of serotoninergic tone 
Serotonin is the most widely distributed transmitter in the brain (Dahlstrom and Fuxe, 1964; 
Steinbusch, 1981). In the mammalian brain, the cell bodies of serotoninergic neurons are 
found in and around the midline raphe nuclei of the brain stem (Dahlstrom and Fuxe, 1964; 
Azmitia and Whitaker-Azmitia, 2000); from these sites, 5HT cells send out the projections 
that innervate the diverse areas throughout the brain and the spinal cord (Figures 5 and 6, Jor-
dan et al., 2008; Tuszynski and Steward, 2012). 
!
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Figure 5. Serotoninergic projections. Schematic diagram showing the locomotor areas and putative pathways at 
brainstem and spinal levels. Blue circles represent neurons of the mediolateral raphe, and red circles represent 
medullary reticulospinal neurons of the locomotor pathway. Neurotransmitters thought to be present in reticu-
lospinal locomotor neurons are indicated. At the spinal level, excitatory (green) and inhibitory (purple) cells rep-
resent neurons of the CPG. Motoneurons are shown in blue and orange (from Jordan et al., 2008). 
!
 
Figure 6. Serotoninergic projections. (a) Retrogradely labeled neurons in the midline raphe and reticular forma-
tion after injections of true blue into the spinal cord of a mouse. Neurons in the raphe nucleus give rise to sero-
toninergic (5HT) axons that project to the spinal cord. (b) Immunofluorescence for 5HT in the thoracic spinal 
cord. CC, central canal. Scale bars, 250 µm. Adapted from Tuszynski and Steward, 2012. 
!
 Accumulating data indicate that 5HT regulates neural plasticity during development 
and in the adult, modulating neural cell proliferation, cell migration and differentiation, neu-
rite outgrowth, axonal guidance, synaptogenesis, and efficiency of trans-synaptic signaling 
(for review Gaspar et al., 2003; Daubert and Condron, 2010). Embryonic 5HT depletion af-
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fects cortical development, reducing dendritic arborization of pyramidal neurons in the so-
matosensory cortex (Vitalis et al., 2007). In vitro research showed that 5HT directs interneu-
ron migration (Vitalis et al., 2007; Riccio et al., 2009), thalamocortical axon pathfinding 
(Bonnin et al., 2007), and GABAergic circuitry maturation in the spinal cord (Allain et al., 
2005). Moreover, besides its role in synapse formation and network construction during de-
velopment, increasing evidence implicates 5HT in the regulation of cell adhesion molecules 
critically involved in the plasticity of the developing and adult brain (Yamagata et al., 2003; 
Dalva et al., 2007). 
 Serotoninergic inputs from the raphe nucleus and parapyramidal region of the ventral 
medulla (Ballion et al., 2002; Jordan et al., 2008) innervate the central pattern generators in 
the spinal cord, neuronal spinal networks capable to generate rhythmic motor activity in the 
absence of rhythmic input from peripheral receptors (CPGs, Grillner and Zangger, 1979; 
Grillner and Wallen, 1985). Experiments in cats demonstrated that pharmacological treat-
ments with agonists of serotonin can evoke or modulate locomotor activity after chronic SCI 
(Barbeau et al., 1981; Barbeau and Rossignol, 1987, 1991; Gerasimenko et al., 2009). These 
results where confirmed in spinalized rodents, where the recovery of locomotor activity was 
achieved with the transplant of embryonic 5HT neurons below the lesion (Feraboli-Lohnherr 
et al., 1997; Ribotta et al., 2000) and administration of 5HTR agonists (Feraboli-Lohnherr et 
al., 1999; Antri et al., 2002, 2003; Landry et al., 2006; Gerasimenko et al., 2007; Ung et al., 
2008; Courtine et al., 2009; Dominici et al., 2012; Musienko et al., 2012).  
 Besides its immediate effect as a neurotransmitter, 5HT has other neurobiological 
functions, especially neurotrophic and neuroprotective effects (Azmitia, 2001). Recent studies 
carried out in animal models highlighted that selective serotonin reuptake inhibitors (SSRIs) , 
a class of drugs clinically used to cure mood disorders and depression, can induce functional 
recovery from neurological impairments due to brain injuries and degenerative diseases in 
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animal models and in patients (Narushima et al., 2007; Li et al., 2009; Yi et al., 2010; Chollet 




After injury, spontaneous recovery of function due to plastic response of injured and unin-
jured circuits has been observed in animal models as well as in patients with an incomplete 
lesion (Raineteau and Schwab, 2001). Since circuitry below the lesion site maintain the capa-
bility to respond to peripheral stimuli, rehabilitative training is a powerful tool to enhance the 
plastic response and increase locomotor recovery. Similarly to what happens during develop-
ment, experience can model connections that are forming after SCI, strengthening active 
synapses and dismissing the less active (Hebb, 1949), than specific training can induce the 
recovery of the exercised function. 
 Rehabilitative training following SCI leads to use-dependent adaptive changes in the 
circuits below the lesion (Lovely et al., 1986; Barbeau and Rossignol, 1987), such as modula-
tion of growth factors, adhesion and guidance molecules expression (Vaynman and Gomez-
Pinilla, 2005; Maier et al., 2008), decreased inhibition (De Leon et al., 1999; Edgerton et al., 
2001; Tillakaratne et al., 2002), increase of sprouting of lesioned and spared descending axons 
(Girgis et al., 2007; Krajacic et al., 2010), and modification of neuronal properties, such as 
motoneuron function normalization (Gardiner et al., 2006; Petruska et al., 2007; Beaumont et 
al., 2008). After rehabilitation, the spinal cord acts as a smart processing interface that contin-
uously integrates multisensory input to control its motor output in partial or total absence of 
brain input (Musienko et al., 2012); moreover, repetitive exposure to specific sensory-motor 
patterns (i.e. the training) leads to the maintaining of a “memory” of these modification (Grau 
et al., 2006; Gomez-Pinilla et al., 2007). 
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 Many experiments demonstrated the efficacy of rehabilitative training in the induction 
of recovery after SCI in animal models and in patients (Barbeau and Rossignol, 1987; Fung et 
al., 1990; Wernig and Muller, 1992; Donaldson et al., 2000; Beekhuizen, 2005; Smith et al., 
2006; Girgis et al., 2007). Most of the studies focused on treadmill training, which has been 
demonstrated to induce recovery of weight supported stepping in case of thoracic incomplete 
injuries (Forssberg et al., 1980a, b; Lovely et al., 1986; Barbeau and Rossignol, 1987; van 
Hedel and Dietz, 2010). Assessing the effect of therapeutic approaches and rehabilitative 
training on forelimb/hand function is more difficult because their functions are much more 
complex (Maier and Schwab, 2006). Nevertheless, training the affected limb gave good re-
sults (Nudo and Milliken, 1996; García-Alías et al., 2009), in particular with the “constraint-
induced therapy”, which consists in the forced use of the affected limb while the unaffected 
limb is constrained (Maier et al., 2008). 
 The efficiency of locomotor rehabilitation is limited by the capability of the subject to 
perform the training, especially when the patient experience a complete lesion and/or is at a 
very old age. To overcome these problems, recently multi-system neurorehabilitation para-
digms have been developed: in these protocols, locomotor training is coupled with epidural 
electrical stimulation and monoamine agonists supply to mimic the loss supraspinal input; this 
strategy leads to the emergence of a new functional state in the spinal cord that enables full 
weight-bearing treadmill locomotion in paralyzed rats that is almost indistinguishable from 
voluntary stepping (Courtine et al., 2009). More recently, the approach has been implemented 
with the use of robotic devices to help completely paralyzed subjects to execute the training. 
Locomotor recovery has been observed in rats as well as in humans (Bishop et al., 2012; Do-
minici et al., 2012; van den Brand et al., 2012). 
 A common strategy in rehabilitative training is to exercise a specific task to recover a 
specific function; unfortunately, it has been often observed that training in one task does not 
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necessarily translate into another (De Leon et al., 1998; Grasso et al., 2004; Smith et al., 2006; 
Bigbee et al., 2007) and, conversely, it can have a detrimental effect on the untrained function 
(De Leon et al., 1998; Bigbee et al., 2007; Girgis et al., 2007; García-Alías et al., 2009). 
Moreover, the combination between training and recovery-promoting treatments led to con-
troversial results, since some studies demonstrated a synergistic effect of combinatorial 
strategies, with an increase of sensory-motor rescue (Kubasak et al., 2008a; Courtine et al., 
2009; García-Alías et al., 2009), while others found that training and/or pro-recovery treat-
ments were more efficient when administered alone, or even detrimental when applied to-
gether (Maier et al., 2009; Harel et al., 2010; Jakeman et al., 2011). It has been suggested that 
these effects could be induced by a bad timing in the application of different strategies, than 
more research about the temporal window to initiate the rehabilitation and to design meaning-
ful treatment combinations needs to be addressed (Fouad and Tetzlaff, 2012). 
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Chapter 4: Aim of the thesis 
In several studies it has been reported that, when SCI is incomplete, processes of partial spon-
taneous recovery may take place, both in animal models as well as in injured patients, and that 
the functional rescue is accompanied by anatomical reorganizations of neural circuits 
(Boulenguez and Vinay, 2009). Therefore, development of treatments aimed at increasing 
plasticity of spinal cord circuits emerges as one of the most promising strategies to restore 
motor function after injury. 
 Fluoxetine, a selective serotonin reuptake inhibitor (SSRIs), is a FDA-approved drug 
widely prescribed in the treatment of various neuropsychiatric disorders. Accumulating evi-
dence suggests that SSRIs can boost neural plasticity in the adult brain, with beneficial effects 
on learning and memory, hippocampal neurogenesis, synaptogenesis and visual cortex plastic-
ity (Malberg et al., 2000; Hajszan et al., 2005; Maya Vetencourt et al., 2008; Li et al., 2009). 
Strikingly, recent studies carried out in animal models and clinical trials highlighted that flu-
oxetine can induce functional recovery from neurological impairments due to brain injuries 
and degenerative diseases (Narushima et al., 2007; Li et al., 2009; Begenisic et al., 2013). In-
deed, it has been demonstrated that an early prescription of fluoxetine coupled with physio-
therapy enhances motor recovery in patients with ischemic stroke (Chollet et al., 2011). 
 In this study, I investigated whether increasing neural plasticity with fluoxetine could 
induce functional recovery in a rat model of spinal cord injury. I tested the impact of fluoxe-
tine on a dorsal funiculi crush at the C4 spinal segment level, a widely studied model of cervi-
cal injury leading to partial loss of sensory inputs to the brain and descending corticospinal 
control of movements. In order to maximize the enhancement of neural plasticity operated by 
fluoxetine, I started the pharmacological treatment three weeks before performing injury, in 
agreement with a number of studies showing that at least 21 days of treatment are required to 
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induce beneficial effects in the central nervous system (Berton and Nestler, 2006; Baudry et 
al., 2010). 
 At first, I analyzed the motor performance of treated and untreated lesioned rats in 
several behavioral paradigms of forelimb function and fine sensorimotor skills. I chose the 
classical Montoya staircase (Montoya et al., 1991) and horizontal ladder (Metz and Whishaw, 
2009) as sensitive tests to evaluate forelimb skilled reaching ability, and the footprint analysis 
of gait (de Medinaceli et al., 1982) as an estimation of general walking behavior of the rat. 
 At the end of behavioral assessment, in order to investigate possible mechanisms un-
derlying the effects elicited by fluoxetine on motor behavior, I injected an anterograde tracer, 
BDA, in the forelimb representation of rat motor cortex, and I analyzed the sprouting of CST 
fibers caudal to the lesion site. Moreover, since serotoninergic axon plastic rearrangement has 
been suggested to be involved in the recovery of motor function after SCI (Sharma et al., 
1990; Inman and Steward, 2003; Camand et al., 2004), I also measured 5HT fiber density 
around the lesion site with immunohistochemistry techniques. 
 Finally, based on the results on motor recovery and induction of anatomical plasticity, 
I examined the molecular changes underlying the enhancement of plasticity induced by three 
weeks of fluoxetine treatment. Given the well-known role of cortical inhibitory circuits in the 
regulation of plasticity time-course (Hensch, 2005; Sale et al., 2010; Baroncelli et al., 2011), I 
analyzed the levels of excitation and inhibition in the motor cortex and the cervical spinal 
cord of uninjured rats by semiquantitative Western Blot for the neurotransmitter transporters 
for glutamate (vGluT-1) and GABA (vGAT) and glutamate and GABA stimulus-evoked over-
flow from synaptosomes. In addiction, I measured BDNF and NT3 neurotrophin expression 
in the cervical spinal cord of treated and untreated rats using semiquantitative Western Blot 
(BDNF) and Enzyme Linked ImmunoSorbent Assay (ELISA, NT3). 
 A schematic diagram of experimental plan is provided in Figure 7. 
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Figure 7. Time-line showing the experimental protocol. Abbreviations: SCI, spinal cord injury; FLX, fluoxetine; 




Materials and Methods 
Animal treatment  
Adult (2-3 months) male Long Evans rats were used in this study, which was approved by the 
Italian Ministry of Health (Decreto N° 182/2011-B, 26/09/2011). Three weeks before spinal 
cord injury (SCI), rats were divided into two groups: control (CTR) and fluoxetine-treated 
(FLX). Fluoxetine (Fluoxetine-hydrochloride, Galeno, Prato-Italy) was administered in the 
drinking water (0.2 g/l) as previously described (Maya Vetencourt et al., 2008), corresponding 
to 16.45±0.36 mg/kg/day. Fluoxetine (or Prozac, Wong et al., 1974) is a highly active 5HT 
reuptake blocker in vitro and in vivo. After oral administration, fluoxetine is almost complete-
ly absorbed. Fluoxetine undergoes extensive metabolic conversion leading to the active me-
tabolite norfluoxetine. Fluoxetine has a half-life of 1 – 4 days, whereas the half-life of norflu-
oxetine ranges between 7 and 15 days (Preskorn, 1997). At least 4 weeks of constant medica-
tion are necessary to reach steady state levels of fluoxetine (Vaswani et al., 2003). In rat, flu-
oxetine wash out requires about 3 days (Caccia et al., 1990). The treatment was not interrupt-
ed immediately after SCI, but continued until the end of the first postoperative week. 
!
Spinal cord injury 
Rats were deeply anesthetized with 1 ml/hg avertin (2.2.2 tribromoethanol solution; Sigma; 
200 mg/kg, i.p.). After shaving the fur between the ears and the scapulae, the skin was sani-
tized with iodine solution (Betadine). A skin incision (2 cm) was performed in correspondence 
of the gap between the occipital bone and the dorsal edge of T2 vertebra. Scissors were in-
serted to blunt dissect the skin from muscles. A pillow was positioned under rat thorax in or-
der to lift up the vertebral column in correspondence of cervical level. Hooks were inserted to 
pull aside the skin and expose muscles, and subsequently the muscle layers were cut along the 
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midline. Using blunt dissection, the superficial muscle layer was separated from the interme-
diate one, which was next blunt dissected from the deep muscle layer. Care was taken in order 
to avoid fat pat damage. The hooks were repositioned to reveal the deep muscle layer overlay-
ing the vertebral column. Using scissors, the vertebral bone was exposed. C4 dorsal process 
was lift up with forceps, and the rostral and caudal ligaments of C4 vertebra were cut; after 
this, the dorsal lamina was removed with fine rongeurs. The dura mater was picked up with 
forceps and cut along the midline; then, 4-5 drops of the local anesthetic lidocaine were ap-
plied onto the spinal cord surface; after 3 minutes, the remaining fluid was removed and the 
spinal cord was rinsed in saline. 
 Spinal cord injury (SCI) was induced inserting the tips of fine forceps 2 mm in depth 
into the spinal cord parenchyma spanning the gap between the dorsal root entries (1.5 mm lat-
eral to the midline) and down to the spinal canal and keeping them closed for 20 seconds. The 
injury included the descending dorsal corticospinal tracts (CSTs) and the ascending sensory 
dorsal columns. In a group of animals (CTR-sham control), only laminectomy was performed, 
without induction of spinal damage. 
 After SCI induction, the intermediate and superficial muscle layers were sutured with 
resorbable thread (Covidien Polysorb 5.0) and the wound was sanitized with Betadine. The 
skin was sutured with surgery staples. At the end of the surgery, rats were injected with de-
sametasone (1 ml/kg, i.p.) and kept in a warm cage until recovery from anesthesia; afterward, 
rats were carried back in their home cage and were treated for 3 days with paracetamol (33 




Montoya Staircase reaching task 
In this task, animals had to grasp and eat sugar pellets (Bio-serv 45 mg Dustless Precision pel-
lets) from a staircase (Campden Instruments Ltd.; Montoya et al., 1991) of seven small wells 
8 mm deep at increasing distance from the rat on either side of a central divider. Before injury, 
rats were food deprived to 90% of free feeding weight to increase their motivation in test per-
formance, then they were trained for three weeks to remove and eat as many sugar pellets as 
possible, until they reached at least 16 pellets eaten on a total of 28 (2 pellets for each well) in 
15 minutes. All the animals that failed to achieve this number were discarded. After SCI, rats 
were tested once a week. Four measures were recorded in this test: eaten pellets, correspond-
ing to the total number of retrieved and eaten; displaced pellets, which are the pellets that the 
rat can touch but not successfully retrieve; accuracy, i.e. the ratio between the number of eaten 
pellets and the sum of eaten and unsuccessfully displaced pellets; reached level, which is a 
measure of the maximum distance reached by the rat. A total of 6 CTR-sham, 13 CTR-inj 
(injured controls) and 10 FLX rats were included in this experiment. 
!
Horizontal ladder  
This task is designed to assess skilled walking in the rat. Briefly, animals were trained to walk 
along an apparatus that consisted of side walls made of clear Plexiglas and metal rungs (3 mm 
diameter), which could be inserted to create a floor with a minimum distance of 1 cm between 
rungs (Metz and Whishaw, 2009). The side walls were 1 m long and 19 cm high, measured 
from the height of the rungs. The ladder was elevated 20 cm above the ground, and a neutral 
start cage and a refuge (home cage) were positioned at each end. The animals were trained to 
cross the ladder from the neutral cage to reach their home cage, so the home cage provided 
the positive reinforcement for walking. Rats were trained for 3 days before injury, with 3 tri-
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als for each session: in the first 2 sessions, the rungs were regularly spaced every 2 cm to al-
low the animals to become confident with the task; during the last session, an irregular pattern 
(with rungs differentially spaced from 1 to 5 cm) was used in order to avoid that the animals 
could learn the pattern.  
 Trials were video recorded over a 60 cm stretch and analyzed offline. The performance 
recorded in the last session was used as baseline measurement. After SCI, rats were tested 
once a week for 6 weeks on an irregular pattern, that was changed for each session. The aver-
age number of forepaw steps made over 3 trials per session and the number of footslips were 
recorded. Accuracy was evaluated as the percentage of correct steps on total. Behavioral test-
ing in the horizontal ladder was performed in a subgroup of the same animals used for the 
Montoya staircase task (N = 6 CTR-sham, 7 CTR-inj and 7 FLX). 
!
Footprint analysis of gait  
This test allows a detailed analysis of motor coordination and synchrony of gait during normal 
walking (de Medinaceli et al., 1982; Brooks and Dunnett, 2009). Before SCI, the fore- and 
hindpaws were painted with dyes of different colors (red for forepaws and blue for hindpaws) 
and rats were encouraged to walk in a straight line along a 80 cm long runway over absorbent 
paper toward home cage. The footprint patterns were then digitalized and analyzed with Pho-
toshop software for stride length, stride width and coordination. 
 Forepaw stride length was determined by measuring the distance between two consec-
utive prints, while stride width was determined by measuring the distance between two con-
secutive right and left forepaw prints. Coordination was measured as the distance between 
forelimb and hindlimb footprints. A series of at least five sequential steps was used to deter-
mine the mean values of each measurement. After injury, animals were tested once a week for 
6 weeks. In this test, in order to avoid possible confounding effects in gait abilities due to 
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practice in other behavioral task, a separate set of animals were used (N = 6 CTR-sham, 9 
CTR-inj and 14 FLX). 
!
Corticospinal tracing and histological assessment  
At the end of the functional evaluation, animals were deeply anesthetized with avertin and 
placed in a stereotaxic frame. With a dental drill, three holes were made bilaterally in the 
skull, over the underlying representation of the forelimbs in the sensorimotor cortex, and 0.25 
µl of 10% biotinylated dextran amine (BDA-10.000, Invitrogen) solution in 0.01M PBS was 
slowly injected using a glass micropipette (Blaubrand) via each burr-hole. BDA was injected 
stereotaxically at a depth of 1.2 mm at six sites distributed over the sensorimotor cortex 
(stereotaxic coordinates: AP 0, ML ± 2; AP +1, ML ± 2; AP 2, ML ± 3). After the last injec-
tion, the skin was sutured and the animals were returned to standard housing conditions for 
three weeks and then were sacrificed by chloral hydrate overdose and transcardially perfused 
with PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer. The brains and the 
C3–C5 spinal cord segments were removed and postfixed in the same solution at 4°C 
overnight, followed by 30% sucrose. Tissue was frozen in Tissue-Tek OCT (Sakura, The 
Netherlands) and transverse 50 µm sections of the medulla oblongata and longitudinal sec-
tions of the C3–C5 spinal segments were cut using a CM 3050S cryostat (Leica Microsys-
tems, Milan, Italy). BDA staining was performed with nickel-enhanced diaminobenzidine 
(DAB) protocol on slides. The accuracy of the lesion was assessed by the quantification of 
spared tissue above the central canal in sagittal sections of the C3-C5 spinal blocks. Animals 
which lesion was too superficial or too deep were excluded from analysis. Corticospinal 
sprouting axons were quantified in the gray matter from the longitudinal sections of the C3–
C5 spinal blocks. Five vertical (0.5 mm, 1.5 mm, 2.5 mm, 3.5 mm, 4.5 mm) lines were super-
imposed on each of at least 10 spinal cord sections (Stereoinvestigator) as reference points for 
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crossing axons starting at the center of the lesion. To correct for variability in BDA uptake by 
CST neurons in the sensorimotor cortex, I normalized the quantitative data by counting BDA-
labeled axons in the main pyramidal tract in three sections of medulla oblongata. A total of 7 
CTR-inj and 7 FLX rats were included in this experiment. 
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Immunohistochemistry 
Perfused cervical spinal cord blocks from CTR-sham, CTR-inj and FLX injured rats were 
frozen in Tissue-Tek OCT (Sakura, The Netherlands) and coronal 50 µm sections of C2 and 
C7 spinal segments were cut using a CM 3050S cryostat (Leica Microsystems, Milan, Italy). 
Sections were collected in serial order on SuperFrostPlus slides (Menzel-Glazer, Germany) 
and incubated for 1 h in a blocking solution (10% normalized goat serum in PBS, pH 7.4) and 
then immunostained overnight at 4°C with a rabbit polyclonal antibody to detect 5HT 
(1:2000, Immunostar). Antigen-antibody binding was revealed with a  goat – anti-rabbit Alexa 
Flour 488 (1:400, Invitrogen) conjugated secondary anti-body. Sections were acquired at 63× 
magnification (1024×1024 pixels) using a confocal Leica microscope. Settings for laser inten-
sity, gain, offset and pinhole were optimized initially and held constant through the analysis. 
 The density of 5HT-IR raphespinal innervation of ventral horn was determined using 
NIH ImageJ version 1.45s. Labeled fibers were selected by thresholding, and average fiber 
length within gray matter was measured after using the skeletonize function in four sections 
per level (C2 or C7) from each rat. A total of 6 CTR-sham, 6 CTR-inj and 8 FLX rats were 
included in this experiment. 
!
Western blot 
Uninjured rats (FLX treated for three weeks and CTR) where decapitated after being deeply 
anesthetized with an overdose of chloral hydrate. Brain and spinal cord where rapidly re-
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moved and the cortical area corresponding to the motor cortex and the cervical (C1-C8) por-
tion of the spinal cord where dissected and frozen at -80°C until processing. Tissue explants 
were homogenized, and proteins were extracted with an isotonic lysis buffer (50 mM Tris HCl 
pH 7.6, 0.01% NP40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1 mM PMSF, 0.1 Na3VO4, 1 
µg/ml leupeptin, 1 µg/ml aprotinin). Total concentration of samples was assessed with a Brad-
ford assay kit (Bio-Rad, Hercules, CA). Fifteen or fifty (respectively, for vGlutT1/vGAT or 
BDNF quantification) micrograms of protein extracts were loaded on Tris-HCl 12% precast 
gels (Bio-Rad) and separated using SDS-PAGE (1 hr at 200 V), then blotted on nitrocellulose 
membrane (Bio-Rad). Blots were blocked using a solution of 4% milk and 0.2% Tween-20 in 
TBS for 2 hr at RT and then probed with anti-vGluT1 (1:2500, rabbit polyclonal antibody, 
Synaptic Systems, Tubingen, Germany), anti-vGAT (1:1000, rabbit polyclonal antibody, 
Synaptic Systems, Tubingen, Germany) or anti-BDNF (1:500, rabbit polyclonal antibody, 
Santa Cruz Biotechnology). Incubation lasted overnight at 4°C. Blots were then incubated 
with 1:20000 horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary anti-body 
(Jackson Immunoresearch, West Grove, PA) for 2 hr at RT. The signal was detected by en-
hanced chemiluminescence (ECL) using the luminol/enhancer system (Immun-Star Western 
C; Bio-Rad) and autoradiography films (HyperFilm; GE Healthcare). As an internal quantifi-
cation standard, blots were also probed for α-tubulin. To do this, blots were blocked again for 
30 min at RT with 5% milk, 0.2% Tween-20 in TBS, with 0.05% sodium azide added to ex-
tinguish the peroxidase activity of the anti-rabbit secondary antibody. Then, blots where incu-
bated with anti-α-tubulin mouse monoclonal antibody (1:10000, Sigma, Germany) for 45 min 
at RT. Finally, blots were reacted with 1:10000 HRP-conjugated goat anti-mouse secondary 
antibody (Sigma-Aldrich Germany) for 45 min at RT and developed with the same ECL 
method. A total of 6 CTR and 6 FLX rats were included in the vGluT1/vGAT experiment, 
while 8 CTR and 8 FLX rats were processed for BDNF. 
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Enzyme Linked ImmunoSorbent Assay (ELISA) 
The NT3 protein was measured with a sandwich ELISA using a NT3 immunoassay system 
(Uscn, Life Science Inc., China), according to the manufacturer's protocol. 
 Proteins from fresh C1-C8 spinal cord segments were extracted with an isotonic lysis 
buffer (50 mM Tris HCl pH 7.6, 0.01% NP40, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1 
mM PMSF, 0.1 Na3VO4, 1 µg/ml leupeptin, 1 µg/ml aprotinin) and the total concentration of 
the samples was assessed with a protein assay kit (Bio-Rad Laboratories Inc., CA, USA) us-
ing a bovine serum albumin (BSA)-based standard curve. The same amount of total proteins 
(in duplicate) and standards (in triplicate) were incubated in the same ELISA plate pre-coated 
with an anti-NT3 polyclonal antibody. Following the incubation and washing steps, an anti-
NT3 monoclonal antibody was applied. Absorbance values were read at 450 nm in a plate 
reader (iMark Microplate Absorbance Reader, Biorad). NT3 levels were calculated from the 
standard curve prepared for the plate, using the Microplate manager software (Bio-Rad). The 
standard curve was linear in the range used (0-10 ng/mL) and the quantities of NT3 used in 




Animals were sacrificed and then the brain and the spinal cord were rapidly removed; motor 
cortex area and cervical spinal cord (C1-C8) were dissected at 4°C. Synaptosomes were pre-
pared essentially as previously described (Milanese et al., 2011). The tissue was homogenized 
at 4°C, utilizing a Teflon/glass homogenizer (clearance 0.25 mm), in 10 volumes of sucrose 
0.32 M, buffered with Tris HCl at pH 7.4. The homogenized tissue was centrifuged (5 min, 
1000 RCF at 4°C) in order to remove nuclei and cellular debris. Then, the supernatant was 
gently stratified on a four steps discontinuous Percoll® gradient (2, 6, 10, 20% v/v in Tris 
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HCl/sucrose) and again centrifuged (5 min, 33500 RCF at 4 °C). After centrifugation, the 
10% and 20% Percoll interface, was collected, washed by centrifugation (15 min, 20200 RCF 
at 4°C) and then resuspended in a physiologic medium (pH 7.4), containing: 140 mM NaCl; 3 
mM KCl; 1.2 mM MgCl2; 1.2 mM CaCl2; 1.2 mM NaH2PO4; 10 mM HEPES; 10 mM glu-
cose. Total concentration of samples was assessed with a Bradford assay kit (Bio-Rad, Her-
cules, CA). A total of 6 CTR and 6 FLX rats were included in this experiment. 
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Release experiments 
Synaptosomes were incubated at 37°C for 15 min; aliquots of synaptosomal suspension were 
layered on microporus filters placed at the bottom of a set of parallel superfusion chambers 
maintained at 37°C (Superfusion System, Ugo Basile, Comerio, Varese, Italy; Tardito et al., 
2010). Superfusion was then started with standard medium at a rate of 0.5 ml/min and contin-
ued for 48 min. After 36 min of superfusion to equilibrate the system, samples were collected 
according to the following scheme: two 3-min samples (t = 36–39 min and t = 45–48 min; 
basal outflow) before and after one 6-min sample (t = 39–45 min; stimulus-evoked release). A 
90 sec period of stimulation was applied at t = 39 min, after the collection of the first sample. 
Stimulation of synaptosomes was performed with 15 mM KCl, substituting for equimolar 
concentration of NaCl. Collected samples were analyzed for endogenous glutamate and 
GABA content. The stimulus-evoked overflow was estimated by subtracting the transmitter 
content of the two 3-min samples (basal outflow) from the release evoked in the 6-min sample 
collected during and after the depolarization pulse (stimulus-evoked release). Aminoacid re-
lease was calculated as pmol/mg of protein and expressed as Glutamate/GABA ratio. 
!
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Neurotransmitter release determination 
Endogenous glutamate and GABA content was measured by high performance liquid chro-
matography analysis following pre-column derivatization with o-phthalaldehyde and gradient 
separation on a C18 reverse-phase chromatographic column (10 x 4.6 mm, 3 µm; at 30°C; 
Chrompack, Middleburg, The Netherlands) coupled with fluorometric detection (excitation 
wavelength 350 nm; emission wavelength 450 nm;). Homoserine was used as an internal 
standard. 
 The following buffers were utilized: solvent A, 0.1 M sodium acetate (pH 5.8)/
methanol, 80 : 20; solvent B, 0.1 M sodium acetate (pH 5.8)/methanol, 20 : 80; solvent C, 
sodium acetate (pH 6.0)/methanol, 80 : 20. The gradient program was as follows: 100% C for 
4 min from the initiation of the program; 90% A and 10% B in 1 min; 42% A and 58% B in 14 
min; 100% B in 1 min; isocratic flow 2 min; 100% C in 3 min; flow rate 0.9 mL/min (Moli-
naro et al., 2013). 
!
Statistical analysis 
Statistical analysis was performed using Sigma Plot 11 (Systat Software, Chicago IL USA).  
 Multiple groups were compared by ANOVA followed by post-hoc comparisons apply-
ing Holm-Sidak test. When two groups were compared, t-test was applied. Normality and 
homoscedasticity of the data was checked. Data not normally distributed were compared us-
ing nonparametric Mann Whitney Rank Sum test (comparison between two groups) and 
Friedman Repeated Measures Analysis of Variance on Ranks (repeated measures). Signifi-




Assessment of the lesion after SCI 
Spinal cord lesion (SCI) was induced in Long Evans male rats inserting fine forceps down in 
the nervous parenchyma sparing the dorsal roots at the level of C4 spinal segments to reach 
the central canal (Figure 8a). This kind of lesion provokes the loss of fine motor control of the 
forelimbs: indeed, it disrupts the ascending sensory fibers of the dorsal columns and the  de-
scending dorsal corticospinal (dCST) axons and partially compromises the gray matter of the 
dorsal horns. Furthermore, it leads to the formation of a cystic cavity full of liquid (Figure 8b-
d). Complete damage to the dCST was verified by observing complete transection of BDA-
traced axons at the lesion site. The depth of the lesion was calculated and normalized on the 
total transverse width of the spinal cord at the injury site. All the animals in which lesion was 
too superficial or too deep were excluded from further analysis. The size and morphology of 
the cystic cavity formed was similar in all the animals and there were no significant differ-
ences between the experimental groups (control injured, CTR-inj, n = 7, median and in-
terquartiles: 63.3, [53.7, 63.7], and fluoxetine treated, FLX, n = 7, 54.2, [53.3, 57.8]. Mann-
Whitney Rank Sum Test, p = 0.165; Figure 8e).  
 Additionally, a group of control rats was subjected to laminectomy without induction 
of spinal damage, in order to discriminate behavioral outcome due to muscular and bone in-
jury from SCI (CTR-sham). 
!
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Figure 8: Spinal cord injury. (a) Representative diagram of rat spinal cord. The red box indicates the dCST 
lesion at C4 level. (b, c). Histological trasverse sections of intact (b) and injured (c) C4 spinal cord. Dashed area 
indicates dCST. (d) Histological sagittal sections of CTR-inj (left) and FLX (right) cervical spinal cord. The star 
indicates the lesion cavity. (e) Quantification of lesion size in CTR-inj (n = 7) and FLX rats (n = 7) as the per-
centage of max transverse width of the spinal cord. There is no statistical difference between the two groups 
(Mann-Whitney Rank Sum Test, p = 0.165). Box-whisker plot: the horizontal lines in the box denote the 25th, 
50th (median), and 75th percentile values; the small square inside the box represents the mean; error bars denote 
the 5th and 95th percentile values. X represents max and min values. Scale bar: 1 mm. Abbreviations: D, dorsal; 
V, ventral; R, rostral; C, caudal. 
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Fluoxetine promotes motor recovery in skilled-task after SCI 
After injury, I analyzed the effects of fluoxetine treatment (FLX, 0.2 g/l in drinking water) on 
rat behavior in several motor tests and compared the performance of FLX group with that of 
CTR-inj and CTR-sham animals. In order to maximize the potential effect of fluoxetine on 
neural plasticity, the treatment started three weeks before SCI, in agreement with a number of 
studies showing that at least 21 days of treatment are required to induce beneficial effects in 
the central nervous system (Berton and Nestler, 2006; Baudry et al., 2010). The treatment was 
continued without interruption until the end of the first postoperative week. 
!
Montoya staircase task 
Rats were tested in the Montoya staircase task (Montoya et al., 1991), which allows to assess 
forelimb skilled reaching ability (Figures 9, 10). Before injury, baseline performance did not 
differ between FLX and CTR animals (Figure 10a-d, eaten pellets: FLX 22.5, [19.0, 23.0], 
CTR 22.0, [18.8, 25.3], Mann-Whitney Rank Sum Test, p = 0.420; displaced pellets: FLX 
22.5, [19.0, 23.0], CTR 22.0, [18.8, 25.3], Mann-Whitney Rank Sum Test, p = 0.763; accura-
cy: FLX 91.0, [87.0, 93.0], CTR 90.0, [80.0, 95.4], Mann-Whitney Rank Sum Test, p = 0.713; 
reached level: FLX 6.25, [5.83, 6.67], CTR 6.50, [6.33, 6.96], Mann-Whitney Rank Sum Test, 
p = 0.257. FLX, n = 10 and CTR, n = 19 for all the measures). One week after SCI, all injured 
rats were unable to grasp and eat pellets, thus confirming the severity of the lesion received; 
moreover, they could not go further than the 4th well (Figure 10d). By the second week post-
surgery, FLX animals (n = 10) began to significantly improve their performance compared to 
CTR-inj rats (n = 13; Two-Way RM ANOVA, post-hoc Holm-Sidak method, p < 0.05 for both 
eaten pellets and accuracy). The improvement resulted in a performance of about 60% of pre-
injury baseline in the sixth week after SCI, when the CTR-inj group displayed only a 30% of 
pre-injury performance (calculated on the accuracy parameter, Figure 10c). The performance 
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of CTR-sham rats (n = 6) did not change throughout the testing period (eaten pellets: One-
Way RM ANOVA, p = 0.095; displaced pellets: Friedman Repeated Measures Analysis of 
Variance on Ranks, p = 0.996; accuracy: One-Way RM ANOVA, p = 0.881; reached level: 
Friedman Repeated Measures Analysis of Variance on Ranks, p = 0.225), demonstrating that 
laminectomy per se does not influence reaching ability in rats. 
 
Figure 9: Fluoxetine induces recovery of grasping behavior after cervical spinal cord injury. (a, b) Pictures 
representing rats performing the staircase task. Before SCI rats learned to retrieve and eat pellets from the stair-




Figure 10: Fluoxetine induces recovery of grasping behavior after cervical spinal cord injury. (a) Quanti-
fication of the number of pellets eaten on the staircase. Starting from the 2nd week, FLX rats began to retrieve 
significantly more pellets than CTR-inj (FLX, n = 10; CTR-inj, n = 13; CTR-sham, n = 6. Two-Way RM AN-
OVA, post-hoc Holm-Sidak method, p < 0.05). (b) Quantification of unsuccessfully displaced pellets. After in-
jury all the lesioned rats displace an higher number of pellets compared to their baseline and to CTR-sham per-
formance (Two-Way RM ANOVA, post-hoc Holm-Sidak method, p < 0.05), indicating that injury affects preci-
sion but not motivation in task performance. (c) Accuracy. Accordingly with the measures obtained from the 
count of eaten pellets, FLX rats showed a greater accuracy (pellets eaten / (pellets displaced + eaten)*100) than 
CTR-inj (Two-Way RM ANOVA, post-hoc Holm-Sidak method, p < 0.05) starting from the 2nd post-SCI week. 
(d) Reached level. Soon after SCI, lesioned rats could not go further than the 4th well. Starting from the 3rd 
week, FLX rats performance is indistinguishable from that of CTR-sham. The performance of CTR-sham rats 
did not change throughout the testing period for all the parameters (eaten pellets: One-Way RM ANOVA, p = 
0.095; displaced pellets: Friedman Repeated Measures Analysis of Variance on Ranks, p = 0.996; accuracy: One-
Way RM ANOVA, p = 0.881; reached level: Friedman Repeated Measures Analysis of Variance on Ranks, p = 
0.225). Box-whisker plot: the horizontal lines in the box denote the 25th, 50th (median), and 75th percentile val-
ues; the small square inside the box represents the mean; error bars denote the 5th and 95th percentile values. X 
represents max and min values. Curves: error bars represent SEM. Symbols indicate statistical difference: CTR-







































































































































I further assessed skilled motor control in SCI rats running on a horizontal ladder (Metz and 
Whishaw, 2009, Figure 11). Baseline performance was equal between FLX and CTR groups 
(footslips mean ± SEM: FLX 2.143 ± 0.240, CTR 2.435 ± 0.225, t-test, p = 0.420; accuracy: 
FLX 84.3 ± 2.62, CTR 83.1 ± 1.24, t-test p = 0.640. FLX, n = 7 and CTR, n = 13 for both the 
measures). However, after injury both FLX and CTR-inj rats showed a dramatic increase in 
the number of errors made at crossing the ladder. I observed a robust acceleration in the time-
course of the recovery process in FLX rats (n = 7) compared to CTR-inj animals (n = 7, Two-
Way RM ANOVA, post-hoc Holm-Sidak method, p < 0.05 for both footslips and accuracy). 
At the conclusion of the testing period, the performance of FLX animals was indistinguish-
able from that of CTR-shams (n = 6, Two-Way RM ANOVA, post-hoc Holm-Sidak method; p 
= 0.190 for footslips and p = 0.065 for accuracy). The performance of CTR-sham rats did not 
change throughout the testing period (footslips: One-Way RM ANOVA, p = 0.672; accuracy: 
One-Way RM ANOVA, p = 0.812). 
!
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Figure 11: Fluoxetine accelerates the recovery of grasping behavior in horizontal ladder task. (a, b) Ex-
amples of rung arrangements: (a) regular; (b) irregular. (c, d) Representative pictures of rats before (c) and after 
(d) injury walking on the ladder. In (c) the animal was unable to correctly place its paws onto the ladder while 
walking across it. (e) Quantification of total forepaw slips. Baseline performance was similar in animals treated 
with FLX and controls (t-test: p = 0.420). After injury, the number of footslips was significantly reduced in FLX 
rats (n =7) compared to CTR-inj (n = 7) starting from the 4th week (Two-Way RM ANOVA, post-hoc Holm-
Sidak method, p < 0.05), while the CTR-sham group (n = 6) maintained the same performance recorded before 
surgery  (One-Way RM ANOVA, p = 0.672). (f) Measure of accuracy (footslips/(total steps)*100) on ladder. 
Fluoxetine treated rats exhibited a more accurate performance than CTR-inj rats at the 4th and 5th week after 
SCI (Two-Way RM ANOVA, post-hoc Holm-Sidak method, p < 0.05). The CTR-sham group maintained the 
same performance throughout the testing period (One-Way RM ANOVA, p = 0.812). Box-whisker plot: the hori-
zontal lines in the box denote the 25th, 50th (median), and 75th percentile values; the small square inside the box 
represents the mean; error bars denote the 5th and 95th percentile values. X represents max and min values. 
Curves: error bars represent SEM. Symbols indicate statistical difference: CTR-sham vs CTR-inj, (#) p < 0.05; 


































































Fluoxetine induces a faster recovery of gait coordination in lesioned rats 
Previous literature showed that a C4 dorsal funiculi crush can induce gait changes, with ani-
mals making shorter and wider frequent forelimb steps; moreover, injured rats displayed poor 
coordination (Bradbury et al., 2002; Garcia-Alias et al., 2008; Wang et al., 2011, Figure 12). 
 In order to study the effects of fluoxetine on walking pattern after SCI, I analyzed 
footprints left by rats as they walked. Baseline performances obtained in a single session be-
fore SCI did not differ between groups (coordination: FLX 1.97 ± 0.118, CTR 1.82 ± 0.106, t-
test, p = 0.367; stride length: FLX 13.323, [11.919, 15.085], CTR 12.258, [12.167, 13.422], 
Mann-Whitney Rank Sum Test, p = 0.169; stride width: FLX 2.231 ± 0.147, CTR 2.341 ± 
0.141, t-test, p = 0.593. FLX, n = 14, CTR, n = 15 for all the measures, Figure 12b-d). The 
assessment was then repeated once a week for six weeks after the induction of the lesion. 
While both injured groups exhibited a reduced coordination in forepaw-hindpaw stepping af-
ter SCI, FLX rats (n = 14) showed a marked recovery of gait coordination compared to CTR-
inj animals (n = 9) three weeks after SCI (Two Way Repeated ANOVA, post hoc Holm-Sidak 
method, p < 0.05, Figure 12b). Otherwise, stride length and stride width did not seem to be 
influenced by the lesion and remained the same recorded before SCI for all the three groups 
(Figures 12c, d). The performance of CTR-sham rats did not change throughout the testing 
period (coordination: One-Way RM ANOVA, p = 0.477; stride length: One-Way RM ANO-
VA, p = 0.145; stride width: One-Way RM ANOVA, p = 0.971). 
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Figure 13: Faster recovery of gait coordination in FLX rats. (a) Typical footprints of animal walking 2 weeks 
after SCI. Red: forepaw footprints; Blue: hindpaw footprints (b) Forepaw-hindpaw footprint distance was used 
to assess the coordination of gait. After injury, FLX rats (n = 14) showed a marked recovery of coordination 
compared to CTR-inj (n = 9) at the 3rd (Two Way Repeated ANOVA, post hoc Holm-Sidak method, p < 0.05) 
and 5th (Two Way Repeated ANOVA, post hoc Holm-Sidak method, p < 0.05) testing week. The performance of 
CTR-sham rats (n = 6) did not change throughout the testing period (One-Way RM ANOVA, p = 0.477). (c) 
Stride length measures. Measures obtained before and after SCI did not differ between groups (baseline: Mann-
Whitney Rank Sum Test, p = 0.169; postoperative weeks: Two Way Repeated ANOVA for treatment, p = 0.475). 
(d) Stride width measures. Measures obtained before and after SCI did not differ between groups (baseline: 
Mann-Whitney Rank Sum Test, p = 0.593; postoperative weeks: Two Way Repeated ANOVA for treatment, p = 
0.459). Box-whisker plot: the horizontal lines in the box denote the 25th, 50th (median), and 75th percentile val-
ues; the small square inside the box represents the mean; error bars denote the 5th and 95th percentile values. X 
represents max and min values. Curves: error bars represent SEM. Symbols indicate statistical difference: CTR-
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Fluoxetine promotes sprouting in the injured spinal cord 
Cervical dorsal funiculi crush results in an interruption of many descending motor and as-
cending sensory spinal tracts, and reestablishment of axonal connections across the injury site 
is fundamental for recovery of forelimb function. Regenerative and compensatory sprouting 
of descending fibers has been indicated as one of the mechanisms allowing spontaneous re-
covery after injury; for example, after cervical SCI in rats, spontaneous sprouting from the 
ventral CSTs occurred onto medial motoneuron pools in the cervical spinal cord, and this was 
correlated with recovery of forelimb function (Weidner et al., 2001). Furthermore, there is ev-
idence that treatments that have been demonstrated to induce recovery of function, such as 
neurotrophin supply, myelin inhibitors and scar degrading agents, act through an increase of 
anatomical plasticity and subsequent formation of new connections in the injured spinal cord 
(Bregman et al., 1997; García-Alías et al., 2009; Lee et al., 2009). 
 Considering that fluoxetine promoted motor recovery in my experiment, I decided to 
study the effects of this treatment on the anatomical plasticity of the descending fibers in-
volved in motor control in SCI rats. 
!
Corticospinal tract (CST) plasticity 
In order to understand if three weeks of fluoxetine could affect the spontaneous response of 
spinal circuits to the lesion, I started analyzing the sprouting of intact ventral corticospinal 
axons (vCST, Weidner et al., 2001).  
 At the end of the behavioral assessment, rats were placed in a stereotactic frame under 
deep anesthesia and the neuronal tracer biotinylated dextran amine (BDA) was bilaterally in-
jected in the forepaw representation area of the sensorimotor cortex (Figure 13a). Animals 
were sacrificed after three weeks to ensure that the tracer reached the lesion site, and perfused 
spinal cords were dissected and processed for diaminobenzidine (DAB) staining. I counted 
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the labeled fibers in the central grey matter of sagittal C3-C5 sections at increasing distances 
from the center of the lesion (Figure 13c, e) in CTR-inj (n = 7) and FLX rats (n = 7). To cor-
rect for variability in BDA uptake by CST neurons in the sensorimotor cortex, quantitative 
data were normalized by counting BDA-labeled axons in the main pyramidal tract of medulla 
oblongata (Figure 13b, d). I found that FLX treatment was able to significantly increase CSTs 
sprouting at 1.5 and 4.5 mm caudal to the lesion compared to CTR-inj rats, in which few or 
none sprouting fibers were observed at any of the considered distances (Two Way ANOVA, p 
< 0.05, Figure 14).  
Figure 14: Fluoxetine increases vCSTs sprouting after SCI. (a) Representative diagram of neuronal tracer 
(BDA) injection in sensorimotor cortex corresponding to forelimb area. After three weeks, it is possible to detect 
the tracer in the spinal cord. (b-e) Representative pictures of fibers traced with BDA and DAB stained. After 
injury, spontaneous compensatory sprouting of the uninjured ventral corticospinal fibers occurs. (b, d) Coronal 
sections of brainstem pyramids of CTR-inj (b) and FLX (d) rats. (c, e) Sagittal sections of C3-C5 spinal sections 
at lesion site of CTR-inj (c) and FLX (e) rats. Scale bar: 50 µm. 
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Figure 14: Fluoxetine increases vCSTs sprouting after SCI. Quantification of sprouting fibers in the ventral 
gray matter at 0.5, 1.5, 2.5, 3.5, 4.5 mm from lesion center normalized on total counts at medulla oblongata level 
(100%). FLX rats (n = 7) showed more sprouting fibers at 1.5 and 4.5 mm caudal to the lesion than CTR-inj (n = 
7). Two Way ANOVA, post hoc Holm.Sidak method. Error bars represent SEM. Stars indicate lesion cavity. Ar-
rows indicate traced sprouting CST fibers. Asterisks indicate statistical significance: (*) p < 0.05. 
!
Serotoninergic fibers 
Raphespinal axons originating in the brainstem descend bilaterally in the lateral columns and 
densely innervate both dorsal and ventral gray matter at all spinal levels (Figures 5, 6, Jordan 
et al., 2008; Tuszynski and Steward, 2012). Previous literature showed that raphespinal fibers 
contribute to locomotion (Lemon, 2008) and to forelimb functional recovery after SCI (Barritt 
et al., 2006; García-Alías et al., 2009; Lee et al., 2009). 
 To determine whether the growth of raphespinal axons is sensitive to fluoxetine ad-
ministration, I assessed the growth pattern of 5HT positive axons in injured rats at C2 and C7 
level, i.e. rostrally and caudally with respect to the lesion. The analysis was focused on the 
ventral horn of the spinal cord, where the serotoninergic fibers synapse on motor neurons 
(Cafferty et al., 2010, Figure 15a-i). I observed a slight increase in neurite density in C2 sec-
tions of injured rats, both CTR-inj (n = 6) and FLX (n = 7), compared to CTR-sham group (n 
= 6), indicating that injury itself induces sprouting of 5HT fibers in the ventral horn, but dif-
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ferences between groups were not statistically significant (5HT fiber density: CTR-sham 91.3, 
[88.4, 119.9], CTR-inj 127.7, [96.7, 208.0], FLX 119.7, [93.8, 207.1], Kruskal-Wallis One 
Way Analysis of Variance on Ranks, p = 0.278, Figure 16a). In addition, no difference was 
observed in the C7 sections, indicating that neither the injury, nor the treatment, seems to af-
fect 5HT axon distribution in the ventral horn caudally to a dorsal funiculi lesion (Figure 17b, 
5HT fiber density: CTR-sham 100 ±17.1, CTR-inj 83.5 ± 10.6, FLX 107.2 ± 15.7, One Way 
ANOVA, p = 0.539. CTR-sham: n = 6; CTR-inj: n = 6; FLX: n = 8). 
Figure 15: Distribution of serotoninergic fibers in the ventral horn. (a-c) Images of the analytical steps ap-
plied for automated quantification of labeled serotoninergic axons: (a) original photomicrograph of C2 ventral 
horn of a CTR-sham rat. Immunofluorescence (gray) shows 5HT signal; (b) threshold transformation of immun-
ofluorescence represented in (a); (c) same image processed in ImageJ for skeletonize function. (d-f) Original 
photomicrographs of C2 ventral horn of a CTR-sham (d), CTR-inj (e) and FLX (f). (g-i) Original photomicro-
graphs of C7 ventral horn of a CTR-sham (g), CTR-inj (h) and FLX (i). Immunofluorescence (green) shows 
5HT signal. Scale bar: 50µm. 
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Figure 16: Distribution of serotoninergic fibers in the ventral horn. (a) Quantification of 5HT axon density 
in C2 ventral horn. No statistical difference was observed among groups (CTR-sham: n = 6; CTR-inj: n = 6, 
FLX: n = 7. Kruskal-Wallis One Way Analysis of Variance on Ranks, p = 0.278). (b) Quantification of 5HT axon 
density in C7 ventral horn. No statistical difference was observed among groups (CTR-sham: n = 6; CTR-inj: n 
= 6, FLX: n = 8. One Way ANOVA, p = 0.539) 
!
Excitation/inhibition balance is modulated by fluoxetine 
The relative strength of the excitatory and inhibitory connections is one major regulator of 
plasticity in the adult central nervous system (Hensch, 2005; Bavelier et al., 2010; Baroncelli 
et al., 2011). Accumulating evidence suggests that fluoxetine acts on excitatory/inhibitory 
balance, and this effect has been correlated with the enhancement of neural plasticity in corti-
cal circuits induced by fluoxetine treatment (Maya Vetencourt et al., 2008; Chen et al., 2011). 
 In order to investigate whether three weeks of fluoxetine treatment were able to pro-
mote molecular changes which might favor plasticity in the motor cortex and in the spinal 
cord, I analyzed the excitation/inhibition balance in control and fluoxetine treated but not in-
jured animals. Three weeks after the beginning of fluoxetine treatment, rats were sacrificed 
and the cervical portion of the spinal cord (C1-C8) and the cortical area corresponding to the 
motor cortex were rapidly dissected and stored for further processing. Tissues obtained from 
age matched rats reared in standard conditions were used as controls. I started with the quan-
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tification of relative expression levels of the vesicular transporter proteins for glutamate (vG-
luT-1 ) and GABA (vGAT) which are, respectively, markers of the excitatory and inhibitory 
cortical tones (Mainardi et al., 2010, Figures 17a, b). Western blot quantification revealed that 
the vGluT-1/vGAT expression ratio was significantly increased in fluoxetine treated animals 
(n = 6) compared to controls (n = 6), both in the motor cortex and in the spinal cord (vGluT1/
vGAT expression ratio in the motor cortex: FLX 1.889 ± 0.204, CTR 1.098 ± 0.178; vGluT1/
vGAT expression ratio in the spinal cord: FLX 2.827 ± 0.565, CTR 1.281 ± 0.367; t-test, p < 
0.05 in both cases, Figure 17b). To confirm this result, I further quantified neurotransmitter 
release in a synaptosomal preparation obtained from cervical spinal cord and motor cortex of 
treated (FLX, n = 6) and untreated (CTR, n = 6) animals (Figure 18a, b). In total agreement 
with the Western-blot results, I found a significant increase of the Glu/GABA stimulus-
evoked overflow ratio in motor cortex and cervical spinal cord synaptosomes of FLX com-
pared to CTR animals (Figure 18b, Glu/GABA stimulus-evoked overflow ratio in the motor 
cortex: FLX 3.7 ± 0.525, CTR 2.3 ± 0.337, t-test, p < 0.05; Glu/GABA stimulus-evoked over-
flow ratio in the spinal cord: FLX 2.59 ± 0.378, CTR 1.34 ± 0.195, t-test, p < 0.01).  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Figure 17: Fluoxetine increases the excitation/inhibition ratio in the motor cortex and the spinal cord. (a) 
Representative Western blots from control or fluoxetine-treated rat motor cortex (left) and spinal cord (right). α-
tubulin was the loading control. (b) Quantification of the expression levels of the vesicular transporter proteins 
for glutamate and GABA (vGluT-1 and vGAT, respectively) by Western blot analysis. The vGluT-1/vGAT ex-
pression ratio was significantly increased after three weeks of fluoxetine treatment, both in the motor cortex and 
in the spinal cord (t-test, p < 0.05 in both cases). Error bars indicate SEM. Asterisks indicate statistical signific-
ance: (**) p < 0.01, (*) p < 0.05. 
Figure 18: Fluoxetine increases the excitation/inhibition ratio in the motor cortex and the spinal cord. (a) 
Schematic diagram showing the synaptosome technique. (b) Quantification of glutamate and GABA released 
after a pulse of 15mM KCl by synaptosomes in superfusion obtained from the motor cortex and the spinal cord. 
The Glu/GABA stimulus-evoked overflow ratio was significantly increased in both the motor cortex and the 
cervical spinal cord tract of FLX compared to CTR animals (t-test, p < 0.05 and p < 0.01, respectively for the 
motor cortex and the spinal cord). Error bars indicate SEM. Asterisks indicate statistical significance: (**) p < 
0.01, (*) p < 0.05. 
!
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Fluoxetine effect on neurotrophin expression in the intact spinal cord 
Previous studies demonstrated that chronic antidepressant treatment up-regulates neurotrophin 
expression in the hippocampus and the cerebral cortex (D'Sa and Duman, 2002; Khawaja et 
al., 2004; Berton and Nestler, 2006). Neurotrophins are known to act as crucial regulators of 
synaptic plasticity and neuronal survival, with increasing amount of data suggesting that neu-
rotrophins, and in particular BDNF and NT3, may play a pivotal role in neuroplasticity after 
stroke and SCI (see Hollis and Tuszynski, 2011 for a review). 
 To address if fluoxetine could act on neurotrophin expression in the spinal cord, and to 
investigate if neurotrophin levels could be involved in motor recovery after SCI in my exper-
iment, I analyzed BDNF and NT3 expression in the cervical spinal cord of rats treated for 
three weeks with fluoxetine. Western blot quantification revealed that BDNF protein expres-
sion was slightly increased in FLX (n = 8) compared to CTR rats (n = 8), but the  difference 
did not reach statistical significance (Figure 19a, b. BDNF expression: FLX 1.464 ± 0.452, 
CTR 0.941 ± 0.237, t-test, p = 0.323,). In addition, quantification of NT3 protein with an En-
zyme Linked ImmunoSorbent Assay (ELISA) revealed that fluoxetine treatment did not influ-
ence the expression of this protein in the cervical spinal cord (Figure 19c. NT3 expression: 
FLX 2.042 ± 0.226, CTR 1.974 ± 0.201, t-test, p = 0.824. FLX, n = 11; CTR, n = 10,).  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Figure 19: Neurotrophins expression. (a) Representative Western blot from control or fluoxetine-treated rat 
spinal cord. α-tubulin was the loading control. (b) Quantification of the expression levels of BDNF by Western 
blot analysis. The increase of BDNF in FLX treated animals is not significant (t-test, p = 0.323). (c) Quantifica-
tion of the expression levels of NT3 by ELISA analysis. Fluoxetine did not change NT3 expression after three 





Fluoxetine enhances motor recovery after spinal cord injury 
Since the appearance of the “monoamine hypothesis” of depression, the development of drugs 
aimed at increasing the serotoninergic tone in the areas involved in the genesis of mood dis-
orders, such as the frontal cortex and the hippocampus, has been strongly encouraged (Wen-
thur et al., 2013). These researches led to the discovery of fluoxetine (Wong et al., 1974), 
which was the first of a new class of antidepressants, the selective serotonin reuptake in-
hibitors (SSRIs). Despite the rapid kinetic of the action of fluoxetine on the 5HT reuptake 
transporter, the antidepressant effects are detectable only after a prolonged administration, 
arguing that other mechanisms should be involved in the response induced by fluoxetine 
treatment (Castren, 2005; Castren and Hen, 2013). 
 Accumulating evidence suggests that fluoxetine can promote neural plasticity in the 
adult brain: recent studies showed that chronic treatment of adult rats with fluoxetine induced 
a plastic state in the visual cortex that closely resembles that observed during the critical peri-
od (Maya Vetencourt et al., 2008). The reinstatement of juvenile like plasticity has also been 
found in a study that used the fear-conditioning paradigm to show that coupling of chronic 
fluoxetine treatment and extinction training increases neuronal plasticity in the amygdala and 
leads to long-term removal of the conditioned fear response (Karpova et al., 2011). Antide-
pressant treatment has been successfully used to counteract the effects of neurodegenerative 
disorders: recently, Cirrito and coworkers demonstrated that chronic treatment with a SSRI, 
citalopram, caused a 50% reduction in brain plaque load in a mouse model of Alzheimer dis-
ease, and retrospective analysis showed that Alzheimer patients treated with antidepressants 
during the past 5 years had significantly less amyloid load as quantified by positron emission 
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tomography (PET) (Cirrito et al., 2011). Fluoxetine administration restored neurogenesis and 
ameliorated hippocampal plasticity in mice models of Down Syndrome (Begenisic et al., 
2013; Stagni et al., 2013). Furthermore, fluoxetine treatment exerted an acute neuroprotective 
effect and promoted hippocampal neurogenesis after experimentally induced ischemia in ro-
dents (Windle and Corbett, 2005; Li et al., 2009; Lim et al., 2009), leading to the beginning of 
clinical trials for SSRIs application in post-stroke therapy (Acler et al., 2009; Jorge et al., 
2010; Chollet et al., 2011). In particular, Chollet and coworkers found that a 3-month treat-
ment with fluoxetine induced a positive effect on motor recovery in patients with acute is-
chaemic stroke (Chollet et al., 2011). 
 In this Thesis, I studied the effects of a long-term treatment with fluoxetine on fore-
limb function after a C4 dorsal funiculi crush in the rat. This kind of lesion leads to partial 
loss of sensory inputs to the brain and descending corticospinal control of movements (Brad-
bury et al., 2002; García-Alías et al., 2009). I analyzed the motor performance of treated and 
control rats using the classical Montoya staircase task (Montoya et al., 1991) and the horizon-
tal ladder test (Metz and Whishaw, 2009) as sensitive assays to evaluate forelimb skilled 
reaching ability, and the footprint analysis of gait (de Medinaceli et al., 1982) as a measure of 
walking behavior. Lesion severity was confirmed by the poor performance recorded in all le-
sioned rats one week after spinal cord injury (SCI) compared to the sham operated group 
(Figures 9-12). After 2-3 weeks, however, fluoxetine treated rats displayed an increased re-
covery of motor performance in fine skills (Staircase, Figure 10; Horizontal ladder, Figure 
11), as well as in general locomotor behavior (Gait analysis, Figure 12). The functional im-
provement that I observed was comparable with the kind of recovery induced by other well 
established treatments acting on neural plasticity, such as chondroitinase ABC (García-Alías 
et al., 2009) and anti-NogoA antibody IN-1 (Merkler et al., 2001). The enhancement of plas-
ticity promoted by fluoxetine was assessed by quantifying the increase of the excitation/inhi-
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bition ratio after three weeks of drug administration (Figures 17, 18). Moreover, the recovery 
process was accompanied by the sprouting of ventral corticospinal (CST) fibers in fluoxetine-
treated animals, measured after the end of the behavioral assessment (Figures 13, 14). 
!
Fluoxetine induces plastic rearrangements in the spinal cord 
Anatomical plasticity 
Several studies reported that partial spontaneous recovery may occur in case of incomplete 
SCI (Boulenguez and Vinay, 2009). Corticospinal tract plasticity has been shown to be the 
main mechanism at the basis of this functional recovery via the formation of new circuits 
through collateral sprouting (Raineteau and Schwab, 2001; Weidner et al., 2001). Weidner et 
al. showed that the functional recovery observed in rats with dCST lesion is abolished after a 
second injury of the ventral CST (vCST), indicating that vCST sprouting compensated the 
lack of innervation due to dCST transection (Weidner et al., 2001). Following this observation 
I analyzed the sprouting of vCST. I found that the number of vCST fibers observed within the 
spinal gray matter was increased in FLX treated rats compared to controls (Figures 13 and 
14). This is in agreement with several works in which recovery of motor function was associ-
ated with an increase of CST sprouting caused by other treatments, such as neutralization of 
inhibitory CNS myelin components (Thallmair et al., 1998; Raineteau et al., 1999; Li and 
Strittmatter, 2003; Li et al., 2004; Li et al., 2005), the enzymatic degradation of glial scar 
(Bradbury et al., 2002; Barritt et al., 2006; Garcia-Alías et al., 2008, 2009; Wang et al., 2011), 
or administration of the neurotrophin NT3 (Schnell et al., 1994; Grill et al., 1997a; Blits et al., 
2000; Tuszynski et al., 2003; Fortun et al., 2009). 
 Besides CST, also serotoninergic fiber sprouting has been associated with motor re-
covery in several SCI models (Sharma et al., 1990; Inman and Steward, 2003; Camand et al., 
2004; Barritt et al., 2006; Lee et al., 2009; Garcìa-Alìas et al., 2009). A large amount of litera-
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ture shows that serotonin is involved in the regulation of locomotion (Cazalets et al., 1992; 
Schmidt and Jordan, 2000; Lemon, 2008). In the mammalian brain, serotoninergic neurons 
are found in and around the midline raphe nuclei of the brain stem (Dahlstrom and Fuxe, 
1964; Azmitia and Whitaker-Azmitia, 2000); from these sites, 5HT positive cells send out the 
projections that innervate the diverse areas throughout the brain and the spinal cord (Figures 6 
and 7, Jordan et al., 2008; Tuszynsky and Steward, 2012). Normally, brainstem-derived 5HT 
facilitates a persistent calcium current in spinal motoneurons and interneurons through 5HT2 
receptors, making spinal neurons ready to respond to fast glutamate synaptic inputs and al-
lowing appropriate muscle contractions (Li et al., 2007; Murray et al., 2010). Moreover, 
pharmacological treatment with serotonin precursors, transplantation of embryonic 5HT neu-
rons or administration of 5HT receptor agonists evoke or modulate locomotor activity after 
chronic SCI (Barbeau et al., 1981; Barbeau and Rossignol, 1991; Feraboli-Lohnherr et al., 
1997; Feraboli-Lohnherr et al., 1999; Ribotta et al., 2000; Antri et al., 2002; Antri et al., 2003; 
Landry et al., 2006; Gerasimenko et al., 2007; Ung et al., 2008; Courtine et al., 2009; Gerasi-
menko et al., 2009; Filli et al., 2011; Musienko et al., 2012; Cristante et al., 2013). 
 To determine whether the growth of raphespinal axons is sensitive to fluoxetine ad-
ministration, I assessed the growth pattern of 5HT-positive axons in the ventral horns of in-
jured rats at C2 and C7 level, i.e. rostrally and caudally with respect to the lesion where sero-
toninergic fibers synapse on motor neurons (Cafferty et al., 2010, Figures 15 and 16). I did 
not observe any difference in the 5HT-positive fiber pattern in fluoxetine-treated rats com-
pared to controls, suggesting that serotoninergic sprouting is not involved in the recovery of 
function after SCI mediated by fluoxetine treatment. 
 An increasing amount of literature shows that the sensory-motor cortex undergoes pro-
found modifications after SCI, and several studies demonstrated that the reorganization of 
cortical circuitry plays a major role during the process of post-lesion recovery (Darian-Smith 
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and Ciferri, 2005; Giszter et al., 2008; Ghosh et al., 2009; Kao et al., 2009; Ghosh et al., 
2010; Kao et al., 2011; Qi et al., 2011). In a recent research, Ganzer and coworkers demon-
strated that the use of 5HT pharmacotherapy promoted a higher degree of circuitry reorgani-
zation in the motor cortex of rats after a complete spinal transection than what would be ex-
pected by transection alone; furthermore, the level of cortical rearrangement positively corre-
lated with the behavioral outcome (Ganzer et al., 2013), confirming the idea that increasing 
cortical plasticity by means of serotoninergic manipulation could be a powerful tool to pro-
mote SCI rescue. In my study, I did not directly assessed the anatomical reorganization of the 
motor cortex; nevertheless, a biochemical analysis revealed that three weeks of fluoxetine 
treatment induced a strong increase of the excitatory/inhibitory balance in this cortical area 
(Figures 17, 18), suggesting that the establishment of a permissive environment for neural 
plasticity in the motor cortex could underlie the recovery of function observed after cervical 
injury. 
!
Involvement of the excitatory/inhibitory balance 
The excitatory/inhibitory balance is a major regulator of plasticity in the central nervous sys-
tem (Berardi et al., 2003; Hensch, 2005; Bavelier et al., 2010; Baroncelli et al., 2011). In my 
experiments, I found that the excitation/inhibition ratio was increased after three weeks of 
fluoxetine treatment in non-lesioned rats, both in the motor cortex and in the spinal cord; thus, 
before the onset of SCI pathophysiology, fluoxetine led to molecular changes that could pro-
mote neural plasticity (Figures 17 and 18). This is in agreement with previous findings on the 
visual cortex (Maya Vetencourt et al., 2008; Chen et al., 2011), and suggests that a modulation 
of GABAergic inhibition accompanied by an increase of glutamatergic release might emerge 
as a critical regulator for plasticity enhancement not only in the adult cerebral cortex but also 
in the spinal cord. 
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 There are various mechanisms through which fluoxetine could lead to the decrease of 
the GABAergic tone. Since the main function of fluoxetine, as a SSRI, is to increase the sero-
toninergic tone, I can hypothesize that the effect on inhibition is mediated by the action of 
5HT on inhibitory interneurons: GABAergic neurons, indeed, appear to be the principal corti-
cal target of 5HT fibers (DeFelipe et al., 1991; Hornung and Celio, 1992; Smiley and Gold-
man-Rakic, 1996), and several experiments demonstrate that 5HT inhibits GABA release 
from interneurons of various brain regions via a presynaptic mechanism mediated by 5HT1/2 
receptor families (Schmitz et al., 1995; Schmitz et al., 1998; Koyama et al., 1999; Zhou and 
Hablitz, 1999; Xiang and Prince, 2003; Bramley et al., 2005; Lee et al., 2008), probably regu-
lating the availability of transmitter vesicles (Wang and Zucker, 1998). Intriguingly, function-
al receptor binding analysis indicated that fluoxetine is an antagonist of 5HT2A and 5HT2C 
receptors (Koch et al., 2002). Furthermore, an increasing amount of data suggests that fluoxe-
tine directly modulates inhibitory transmission: recent studies showed that the application of 
clinically relevant amounts of fluoxetine on hippocampal slices can induce a reduction of 
GABAergic signaling, both in the presence or in the absence of other SSRIs, thus demonstrat-
ing that the action of fluoxetine on the reduction of GABAergic transmission can be indepen-
dent from serotonin (Mendez et al., 2012; Caiati and Cherubini, 2013). The results presented 
in these papers indicate that fluoxetine alters the release of GABA from the presynaptic ter-
minal in the hippocampus; this is in accord with my findings, which show that three weeks of 
fluoxetine treatment induced a reduced expression of vGAT, the transporter that mediates the 
accumulation of GABA into synaptic vesicles, and the decrease of the evoked GABA release 
from synaptosomes in the motor cortex and in the spinal cord (Figures 17, 18). 
 The decrease of inhibitory signaling was accompanied by the increase of glutamater-
gic transmission, which was measured through vGluT1 expression and glutamate release 
quantification (Figures 17, 18). My results are in agreement with previous literature: indeed, 
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fluoxetine treatment enhanced vGluT1 mRNA expression in the hippocampus and in frontal, 
orbital, cingulate and parietal cortices in rats (Tordera et al., 2005). Furthermore, in chronical-
ly treated rats fluoxetine induced selective changes in glutamate receptor subunits which were 
associated with structural plasticity, and in particular with the upregulation of dendritic spine 
density and of large, mushroom-type spines in the cerebral cortex (Ampuero et al., 2010). 




Previous studies demonstrated that chronic antidepressant treatment up-regulates neurotrophin 
expression, especially BDNF, in the hippocampus and the cerebral cortex (D'Sa and Duman, 
2002; Khawaja et al., 2004; Berton and Nestler, 2006; Martinowich et al., 2007; Maya Veten-
court et al., 2008). Neurotrophins are known to be crucial regulators of synaptic plasticity and 
neuronal survival (Poo, 2001; Berardi et al., 2003), and an increasing amount of data suggest 
that neurotrophins, and in particular BDNF and NT3, may play a pivotal role in neuroplastici-
ty after SCI (Schnell et al., 1994; Giehl and Tetzlaff, 1996; Grill et al., 1997a; Kobayashi et 
al., 1997; Bradbury et al., 1999; Liu et al., 1999; Blits et al., 2000; Lu et al., 2001; Jin et al., 
2002; Tuszynski et al., 2003; Ruitenberg et al., 2004; Lu et al., 2005; Taylor et al., 2006a; Alto 
et al., 2009; Fortun et al., 2009; Brock et al., 2010). 
 To address if fluoxetine could act on neurotrophin expression in the spinal cord, and 
to investigate if neurotrophin levels could be involved in motor recovery after SCI in my ex-
periment, I analyzed BDNF and NT3 expression in the cervical spinal cord of rats treated for 
three weeks with fluoxetine (Figure 19). My results show an increase, albeit not significant, of 
BDNF expression in fluoxetine treated rats, while NT3 levels were not affected. These results 
are not completely surprising, since previous literature showed that chronic fluoxetine in-
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creased BDNF expression in the hippocampus but not in the spinal cord (Engesser-Cesar et 
al., 2007). However, since I did not evaluate neurotrophin concentration in the lesioned spinal 
cord of treated and control rats, I can not exclude the possibility that fluoxetine could act by 
counteracting the depletion of neurotrophic support which has been described after SCI 
(Nakamura and Bregman, 2001). 
 Furthermore, fluoxetine could increase BDNF expression in the motor cortex, where 
the CST fibers originate: several studies demonstrated that BDNF administration near the cell 
soma increases CST neurons survival after subcortical lesion (Giehl and Tetzlaff, 1996; Lu et 
al., 2001), then it is tempting to speculate that fluoxetine could exert a neuroprotective effect 
through BDNF in the motor cortex of fluoxetine treated rats. 
!
Conclusions and future directions 
The results presented in this Thesis show that the establishment of a more permissive envi-
ronment through prolonged fluoxetine administration can enhance plasticity in the spinal cord 
and that this might favor recovery from SCI. A similar link between neural plasticity en-
hancement and functional improvement after SCI has been previously demonstrated for other 
treatments, such as chondroitinase ABC (García-Alías et al., 2009) and anti-NogoA antibody 
IN-1 (Merkler et al., 2001). In line with these studies, future work will focus on the potential-
ly beneficial effects of post lesion treatment with fluoxetine. Given that fluoxetine requires a 
prolonged administration period to achieve its functional effects, it is likely that a protocol 
based on initiating fluoxetine administration immediately after SCI might represent a good 
strategy to induce recovery. Furthermore, it will be interesting to address the effects of fluoxe-
tine in combination with sensory-motor rehabilitation. In agreement with this possibility, posi-
tive effects of fluoxetine coupled with physiotherapy have been recently shown in patients 
with ischemic stroke (Chollet et al., 2011). 
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 The non invasive nature of the pharmacological paradigm reported in this study makes 
fluoxetine administration a treatment with a great potential for clinical application in the field 











Appendix: A rich environmental experience reactivates 
visual cortex plasticity in aged rats.  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Introduction 
In the past few decades, decreased birth rate and longer life expectancy due to improved envi-
ronmental conditions and medical assistance caused a marked world population aging and the 
emergence of age-related diseases as major determinants of human mortality. Complementary 
to efforts aimed at the characterization of pathological aging, defining cellular and molecular 
mechanisms underlying normal aging and finding tools capable to prevent or reverse age-re-
lated decline in the organism function are primary goals of both basic and clinical research in 
Neuroscience (Bishop et al., 2010). 
 The brain aging process is typically associated with functional deterioration across 
multiple systems, including cognitive and sensory-motor domains, that can, in part, be ex-
plained by a progressive decay of neural plasticity, i.e. the capacity to reorganize cerebral cir-
cuits in response to instructive and adaptive signals from the surrounding environment (Burke 
and Barnes, 2006). Despite the increasing evidence that environmental enrichment (EE) at-
tenuates age-related cognitive deficits (Frick and Benoit, 2010), little is known about the ef-
fects of enhanced environmental stimulation on experience-dependent plasticity processes in 
the cerebral cortex of aging animals. The visual system stands as the prime model for study-
ing neuronal plasticity. Occluding one eye early in development (monocular deprivation, MD) 
leads to an ocular dominance (OD) shift of cortical neurons, that is, a reduction in the number 
of cortical cells responding to that eye and a robust increment in the number of neurons acti-
vated by the open eye. The same treatment is completely ineffective in the adult organism 
(Berardi et al., 2000). 
 Recently, studies conducted in this laboratory challenged this dogma, demonstrating 
that EE in adult animals reactivates juvenile-like OD plasticity in the visual cortex (Baroncelli 
et al., 2010). In the effort to start studying whether exposure to enhanced stimulating condi-
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tions might favor experience-dependent plasticity in aged rats, I used in vivo electrophysio-
logical recordings to measure OD plasticity in the visual cortex of monocularly-deprived aged 
rats exposed to either EE or normal standard rearing conditions. I provide evidence that aged 
rats are still sensitive to the reinstatement of plasticity induced by EE.  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Materials and methods 
Animal treatment 
A total of 27 female Long-Evans hooded rats (350-400 g) were used in this study, approved 
by the Italian Ministry of Public Health. At 22-23 months of age the animals were transferred 
for three weeks to an environmental enrichment (EE) setting or maintained in standard condi-
tions (SC). Environmental enrichment consisted of a large cage (100x50x82 cm) with three 
floors linked by stairs, containing several food hoppers, free-access running wheels (diameter 
25 cm) and differently shaped objects, which were substituted with others at least once a 
week. Every cage housed 6-8 adult rats. Standard condition consisted of a smaller cage 
(40x30x20 cm) housing 2-3 adult rats. In both environmental conditions, animals were main-
tained at 21°C under a 12-h light/dark cycle and had ad libitum access to food and water. Af-
ter 15 days in EE or SC, a group of rats was anesthetized with avertin (2.2.2 tribromoethanol 
solution; Sigma; 200 mg/kg, i.p.). Monocular deprivation (MD) was performed through eyelid 
suturing, after which the animals were returned to their respective housing conditions. Sub-
jects with even minimal spontaneous eyelid re-opening were excluded from the study. 
!
In vivo Electrophysiology 
After 1 week of MD, animals were anesthetized with urethane (20% solution in saline; Sigma; 
i.p. injection; 0.5 ml/100g) and placed in a stereotaxic frame. Body temperature was main-
tained at 37°C. A hole was drilled in the skull, corresponding to the binocular portion of the 
primary visual cortex (binocular area, Oc1B) contralateral to the deprived eye. After the expo-
sure of the brain surface, a micropipette filled with NaCl (3 M) was inserted into the cortex 5 
mm lateral to the λ point. Both eyes were fixed and kept open by means of adjustable metal 
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rings surrounding the external portion of the eye bulb. The eyes were frequently inspected and 
rinsed with physiological solution to prevent the formation of cataracts. 
!
VEP recordings 
Ocular dominance (OD) was measured by calculating the contralateral to ipsilateral ratio of 
visual evoked potentials (VEPs), that is, the ratio of VEP amplitudes recorded by stimulating 
the eye contralateral and ipsilateral, respectively, to the visual cortex where the recording was 
performed. The electrode was advanced at a depth of 100 or 500 µm within the cortex, where 
VEPs had their maximal amplitude. Visual stimuli were horizontal sinusoidal gratings with a 
spatial frequency of 0.1 c/deg, generated by a VSG2/2 card running custom software, present-
ed on a monitor positioned 20 cm from the rat’s eyes, and centered on the previously deter-
mined receptive fields. Signals were band-pass-filtered (0.1–100 Hz), amplified, and fed to a 
computer for analysis. At least 128 events were averaged in synchrony with the stimulus con-
trast reversal. Transient VEPs in response to abrupt contrast reversal (0.5 Hz) were evaluated 
in the time domain by measuring the peak-to-baseline amplitude and peak latency. To prevent 
sampling bias, at least three penetrations were performed for each animal. Care was taken to 




Single-unit recordings were used to further assess plasticity in response to MD. Spontaneous 
activity, peak response and receptive field size were determined from peri-stimulus time his-
tograms recorded in response to computer-generated bars (size: 3°; drifting speed: 38.15 °/
sec; contrast: 100%), averaged over 15 stimulus presentations. Ocular dominance classes 
were evaluated according to the method of Hubel and Wiesel. For each animal, the bias of the 
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OD distribution toward the contralateral eye [contralateral bias index (CBI)] was calculated as 
follows: CBI = [(N(1) – N(7)) + 2/3 (N(2) – N(6)) + 1/3 (N(3) – N(5)) + NTOT]/2NTOT, 
where N(i) is the number of cells in class i, and NTOT is the total number of recorded cells in 
a specific animal. Additionally, for each cell an OD score was calculated as follows: 
{[peak(ipsi) – baseline(ipsi)] – [peak(contra) – baseline(contra)]}/{[peak(ipsi) – 
baseline(ipsi)] + [peak(contra) – baseline(contra]}, where peak is the maximal spike frequen-
cy evoked by visual stimulation, ipsi is the ipsilateral eye, baseline is the mean spiking fre-
quency in the absence of stimulation, and contra is the contralateral eye. OD score cumulative 
distributions were computed for each group. 
!
Immunohistochemistry 
Visual cortex samples were collected from not deprived aged animals reared in SC or exposed 
to EE for 15 days in order to evaluate whether EE led to molecular changes, which could be 
permissive for plasticity recovery. Animals were anesthetized with an overdose of chloral hy-
drate (10% in saline; Sigma) and perfused transcardially with phosphate buffered saline (10 
mM; PBS) followed by fixative (4% paraformaldehyde, 0.1 M sodium phosphate, pH 7.4). 
Brains were removed and post-fixed for 6 hrs in the same fixative at 4°C, before being im-
mersed in 30% sucrose. Free-floating sections were incubated for 1 h in a blocking solution 
(10% BSA in PBS, pH 7.4) and then overnight at 4°C in a solution of anti-GAD67 antibody 
(MAB 5406, 1:1000, Chemicon) or biotin-conjugated lectin Wisteria Floribunda Agglutinin 
(WFA, L1516, 10µg/ml, Sigma). Antigen-antibody binding was revealed, respectively, with 
Alexa Fluor 448 goat anti-mouse (1:400, Molecular Probes) and fluorescein-conjugated ex-
travidin (1:400, Sigma). Sections of the two experimental groups were reacted together with 
the same immunohistochemical procedure. Sections were acquired at 32x magnification 
(1024x1024 pixels) using a confocal Leica microscope to analyze the number of GAD67-pos-
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itive cells and WFA-positive perineuronal nets (PNNs). Settings for laser intensity, gain, off-
set and pinhole were optimized initially and held constant through the analysis. Images were 
imported to the image analysis system MetaMorph and counts were done in blind on the en-
tire thickness of Oc1B. For each animal, at least five Oc1B sections were analyzed. 
!
Statistical analysis 
Statistical analysis was performed using Sigma Stat 3.5. Normality and homoscedasticity of 
the data were checked. Multiple groups were compared by ANOVA followed by post-hoc 
Holm-Sidak test. Two-tailed t-test was applied in case of comparisons between only two 
groups. Differences between OD distributions were assessed using a χ2 test. For OD score, 




I evaluated OD plasticity in aged rats (22-23 months) housed either in environmental enrich-
ment (EE) or in standard conditions (SC). Detrimental effects of aging, indeed, are self-evi-
dent in rats only after 20 months of age, with broadly expressed signs of deterioration in the 
limbic and sensory-motor systems not recognizable in younger adult animals (Frick and 
Benoit, 2010). After 7 days of MD, I recorded visual evoked potentials (VEPs) from Oc1B 
contralateral to the occluded eye, calculating the contralateral-to-ipsilateral (C/I) VEP ratio as 
a measure of OD properties of cortical neurons. While MD did not affect the C/I VEP ratio in 
SC animals (MD-SC, n = 5, C/I VEP ratio: 2.04 ± 0.13; One-Way ANOVA, post-hoc Holm 
Sidak method, p = 0.09), I observed a marked OD shift in monocularly-deprived EE rats 
(MD-EE, n = 5, C/I VEP ratio: 1.11 ± 0.14) with respect to that measured in SC animals not 
subjected to MD (n = 8, C/I VEP ratio: 2.39 ± 0.13; p < 0.001; Figure 20a). 
 I further assessed OD plasticity using extracellular single-unit recordings. Contralater-
al bias index (CBI) and OD class distribution of MD-SC (n = 4, CBI: 0.63 ± 0.05) animals did 
not differ from those measured in SC rats (n = 9, CBI: 0.65 ± 0.03; One-Way ANOVA, post-
hoc Holm Sidak method for CBI comparison, p = 0.745; χ2 test for OD class distribution 
comparison, p = 0.593), whereas a significant OD shift in favor of the open eye was detected 
in MD-EE animals compared to the SC group (n = 6, CBI: 0.54 ± 0.03; respectively, p < 0.05, 
p < 0.001; Figure 20b,c). Accordingly, the cumulative distributions of OD score in SC (216 
cells) and MD-SC animals (93 cells) were completely superimposable (Kolmogorov-Smirnov 
test, p = 0.584); in contrast, MD-EE rats (130 cells) showed an OD distribution shifted to-
wards the open eye and significantly different with respect to SC rats (p < 0.05; Figure 20d). I 
also checked that EE did not affect basic physiological response properties of visual cortical 
neurons, with both VEP and single-unit recordings. No differences among SC (contra: 115.23 
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± 7.48 ms; ipsi: 125.86 ± 6.36 ms), MD-SC (contra: 110.81 ± 4 ms; ipsi: 126.38 ± 3.55 ms) 
and MD-EE animals (contra: 116.13  ± 3.89 ms; ipsi: 125.15  ± 4.76 ms) were detected either 
in VEP latency values for both eyes (Two-Way Repeated Measures ANOVA, p = 0.963; Fig-
ure 21a), or in the spontaneous discharge of cortical neurons (SC: 1.11 ± 0.18 spike/s, MD-
SC: 1.23 ± 0.37 spike/s, MD-EE groups; 0.78 ± 0.21 spike/s; One-Way ANOVA, p = 0.449; 
Figure 21b) or in the receptive field size distribution of the cell population (SC: 15.22 ± 1.46°, 
MD-SC: 16.25 ± 0.75°, MD-EE: 14.21 ± 1.47°; p = 0.661; Figure 21c).  
 Since a reduction of GABAergic transmission has been identified as a crucial hub for 
the restoration of plasticity processes in the adult brain (for recent reviews, see Bavelier et al., 
2010 and Baroncelli et al., 2011), I quantified GAD67-positive cells (GAD67+) in the visual 
cortex of SC and EE animals by means of semi-quantitative immunohistochemistry. The 
number of GAD67+ interneurons normalized to the area of Oc1B was statistically lower in EE 
rats (n = 4, 80 ± 5.63 cells/mm2) with respect to SC animals (n = 3, 137.69 ± 6.9 cells/mm2; t-
test, p = 0.001; Figure 22). Moreover, since the degradation of extracellular matrix perineu-
ronal nets (PNNs) has been related to the reopening of cortical plasticity in the adult brain 
(Pizzorusso et al., 2002; Kwok et al., 2011), I examined PNN distribution in the visual cortex 
of SC and EE animals. Environmental enrichment led to a significant reduction in the density 
of PNNs in the visual cortex of aged rats (EE: n = 4, 78.67 ± 6.08 PNNs/mm2) with respect to 
SC (n = 4, 108.4 ± 7.27 PNNs/mm2; t-test, p < 0.05; Figure 23).  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Figure 20. Environmental enrichment (EE) reactivates ocular dominance (OD) plasticity in the aged visual 
cortex. (a) VEP recordings revealed that, with respect to SC rats (n = 8), MD did not affect the C/I VEP ratio in 
MD-SC animals (n = 5; One-Way ANOVA, post-hoc Holm Sidak method, p = 0.09), whereas a significant de-
crease in the C/I VEP ratio of MD-EE animals was evident (n = 5; p < 0.001). (b) CBI values for SC, MD-SC 
and MD-EE groups obtained by single-cell activity recordings. Larger symbols represent the average CBI ± 
SEM for each experimental group; smaller symbols represent individual CBIs for each animal. The CBI of MD-
SC rats (n = 4) did not significantly differ from that of SC animals (n = 9; One-Way ANOVA, post-hoc Holm 
Sidak method, p = 0.745), whereas the CBI of MD-EE rats was lower compared to that of the SC group (n = 6; p 
< 0.05). (c) A χ2 test showed that OD distributions for SC and MD-SC rats were superimposable (p = 0.593), 
whereas a significant OD shift towards the open eye was evident in MD-EE animals with respect to the SC 
group (p < 0.001). (d) OD score distributions for SC (216 cells) and MD-SC animals (93 cells) did not signific-
antly differ (Kolmogorov-Smirnov test, p = 0.584) between each other, whereas OD score distribution for MD-
EE group (130 cells) was statistically different from that of the SC group (p < 0.05). Asterisks indicate statistical 
significance: (*) p < 0.05; (***) p < 0.001. Error bars represent SEM.  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Figure 21. Environmental enrichment (EE) reactivates ocular dominance (OD) plasticity in the aged visual 
cortex. (a) VEP latencies obtained by alternatively stimulating the contralateral and the ipsilateral eye with re-
spect to the recorded cortex at the spatial frequency of 0.1 c/deg were not different in SC, MD-SC and MD-EE 
animals (Two-Way Repeated Measures ANOVA, p = 0.963). (b) No statistical difference in spontaneous dis-
charge of cortical neurons was present among SC, MD-SC and MD-EE groups (One-Way ANOVA, p = 0.449). 
(c) EE exposure did not alter the receptive field (RF) size distribution of the cell population (One-Way ANOVA, 
p = 0.661). Asterisks indicate statistical significance: (*) p < 0.05; (***) p < 0.001. Error bars represent SEM. 
!
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Figure 22. A role for intracortical inhibition in the induction of EE-dependent plasticity in the aged visual 
cortex. (a) Density of cells positive for GAD67 (GAD67+) in the entire thickness of the visual cortex was lower 
in EE animals (n = 4) with respect to SC rats (n = 3; t-test, p = 0.001). Cell density in EE visual cortex was nor-
malized to the mean value in the SC cortex. (b) Illustrative images showing the reduction of GAD67+ cells in 
the visual cortex of EE animals. Arrows indicate representative examples of GAD67+ cells considered for quan-




Figure 23. A role for extracellular matrix in the induction of EE-dependent plasticity in the aged visual 
cortex. (a) The number of WFA positive PNNs (WFA+) in the entire thickness of the visual cortex was signific-
antly reduced in EE animals (n = 4) with respect to SC rats (n = 4; t-test p < 0.05). Density of WFA+ PNNs in 
EE visual cortex was normalized to the mean value in the SC cortex. (b) Illustrative images showing the reduc-
tion of WFA+ PNNs in the visual cortex of EE animals. Arrows indicate representative examples of WFA+ 
PNNs considered for quantification. Calibration bar: 100 µm. Asterisks indicate statistical significance: (*) p < 
0.05. Error bars represent SEM.  
!110
Discussion 
I have demonstrated that an enhanced environmental stimulation is able to restore OD plastic-
ity in the aging visual cortex. To make sure that plasticity was not present only at the level of 
subthreshold modifications of postsynaptic potentials (detected by VEPs), I measured OD 
properties of cortical neurons also using single-cell recordings. I reported a significant OD 
shift in the visual cortex contralateral to the deprived eye in MD-EE animals, though slightly 
lower with respect to that measured in similarly treated adult rats (Baroncelli et al., 2010). 
Even if a connection between neural plasticity and EE in the aging brain has been suggested 
by previous results (e.g. Kempermann et al., 1998; Frick and Fernandez, 2003), this is the first 
time that the highly reliable and informative paradigm of OD plasticity has been studied in 
old rats. 
 It is generally assumed that EE provides the animals with a combination of multi-sen-
sory and cognitive stimulation, high levels of physical activity, enhanced social interactions, 
and incentivizes explorative behavior, play, curiosity and attentional processes. I can speculate 
that this condition strongly increases the arousal state of animals setting in motion a molecular 
chain of factors that finally promote neural plasticity (see also Baroncelli et al., 2010). The 
excitatory-inhibitory balance is crucially involved in the regulation of plasticity during devel-
opment and in adulthood (Bavelier et al., 2010; Baroncelli et al., 2011) and a decrease of in-
tracortical inhibition levels is required for the reinstatement of neural plasticity elicited by EE 
in the adult visual cortex (Sale et al., 2007; Baroncelli et al., 2010). This correlation turned 
out to be true also in aged EE animals. Indeed, I found that the number of GAD67+ cells in 
the visual cortex of EE rats was lower compared to that obtained for SC animals. Moreover, 
the decrease in GAD67-expressing neurons was accompanied by a remodeling of the extracel-
lular matrix (ECM), with a significant reduction in the density of PNNs in the visual cortex of 
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EE rats with respect to SC. It is well-known that the extracellular milieu is one of the prime 
structural brake limiting brain plasticity in adulthood (Pizzorusso et al., 2002; Kwok et al., 
2011) and the permissive action of ECM degradation on cortical plasticity could occur 
through a direct structural and functional remodeling of inhibitory synapses. My results sug-
gest that molecular factors, which are known to be critically involved in the reinstatement of 
plasticity in the adult brain, may also underlie the EE effects in the aging visual cortex. 
 Given the complex nature of the EE setting and its capability to modify the cerebral 
biochemical milieu promoting visual cortex plasticity, I can assume that EE-dependent bene-
ficial effects might be detected throughout the entire brain. Since deterioration in functional 
plasticity contributes to the decline of cognitive and sensory-motor abilities occurring during 
normal aging (Burke and Barnes, 2006), EE emerges as an elective strategy to counteract be-
havioral alterations observed in age-related disorders. It has been previously shown, indeed, 
that EE in aged rodents is able to promote an improvement of complex cognitive functions, 
accompanied by prominent changes at the anatomical and molecular level (for a recent over-
view, see Frick and Benoit, 2010). 
 Laboratory rodents are a powerful model system sharing many homologies with hu-
mans at the genetic and the physiological levels so that conclusions drawn in one species can 
be used to approach similar issues in the other. My results suggest that is never too late for the 
brain to get on track towards a rich environmental experience, encouraging the development 
of intervention protocols based on enriched experience aimed at maintaining a healthy and 
active lifestyle in aging people. Accordingly, strong correlative and epidemiological evidence 
shows that living habits, including occupation, leisure activities and physical exercise, has a 
direct effect on the risk of cognitive decline, with an increasing number of results indicating 
that a higher level and variety of mental and physical activity is associated with a lower cog-
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